Biodelivery Sciences International (BDSI) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 11, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'BIODELIVERY SCIENCES INTERNATIONAL INC	'	'
Entity Central Index Key	'0001103021	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	47,932,326	'
Entity Public Float	'	'	$134,206,938

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$23,175,809	$63,189,307
Accounts receivable	2,794,040	520,812
Prepaid expenses and other current assets	630,657	226,064
Total current assets	26,600,506	63,936,183
Equipment, net	178,168	2,835,707
Idle equipment, net (note 1)	2,844,718	'
Goodwill	2,715,000	2,715,000
Other intangible assets:	'	'
Licenses	1,900,000	1,900,000
Acquired product rights	9,050,000	9,050,000
Accumulated amortization	-5,753,502	-4,770,516
Total other intangible assets	5,196,498	6,179,484
Derivative asset, warrant	'	50,300
Other assets	470,535	21,976
Total assets	38,005,425	75,738,650
Current liabilities:	'	'
Accounts payable and accrued liabilities	10,415,981	10,755,049
Notes payable, current maturities	7,333,333	'
Deferred revenue, current (notes 5 and 6)	2,927,088	7,990,231
Derivative liabilities (note 10)	4,315,183	4,497,977
Total current liabilities	24,991,585	23,243,257
Notes payable, less current maturities	11,844,706	'
Deferred revenue, long-term	1,281,485	2,718,180
Other long-term liabilities	700,000	'
Total liabilities	38,817,776	25,961,437
Commitments and contingencies (notes 10 and 14)	'	'
Stockholders' (deficit) equity:	'	'
Preferred Stock, $.001 par value; 5,000,000 shares authorized in 2013 and 2012; 2,709,300 shares of Series A Non-Voting Convertible Preferred Stock outstanding in 2013 and 2012	2,709	2,709
Common Stock, $.001 par value; 75,000,000 shares authorized in 2013 and 2012; 38,204,384 and 37,497,703 shares issued; 38,188,893 and 37,482,212 shares outstanding in 2013 and 2012, respectively	38,204	37,499
Additional paid-in capital	150,506,927	143,703,583
Treasury stock, at cost, 15,491 shares, 2013 and 2012	-47,183	-47,183
Accumulated deficit	-151,313,008	-93,919,395
Total stockholders' (deficit) equity	-812,351	49,777,213
Total liabilities and stockholders' (deficit) equity	$38,005,425	$75,738,650

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
			Series A Non-Voting Convertible Preferred Stock [Member]	Series A Non-Voting Convertible Preferred Stock [Member]
Preferred Stock, par value	$0.00	$0.00	'	'
Preferred Stock, shares authorized	5,000,000	5,000,000	'	'
Preferred Stock, shares outstanding	'	'	2,709,300	2,709,300
Common Stock, par value	$0.00	$0.00	'	'
Common Stock, shares authorized	75,000,000	75,000,000	'	'
Common Stock, shares issued	38,204,384	37,497,703	'	'
Common Stock, shares outstanding	38,188,893	37,482,212	'	'
Treasury stock, shares	15,491	15,491	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product royalty revenues	$1,773,215	$1,082,742	$2,716,452
Research revenue	'	13,375	227,668
Research and development reimbursements	2,782,830	'	'
Contract revenue	6,799,838	53,446,309	318,800
Total revenues	11,355,883	54,542,426	3,262,920
Cost of product royalties	2,082,183	1,909,785	1,756,629
Expenses:	'	'	'
Research and development	53,326,777	35,365,662	20,805,177
General and administrative	12,302,364	10,114,689	7,608,090
Related party general and administrative	46,500	90,500	81,000
Total expenses	65,675,641	45,570,851	28,494,267
(Loss) income from operations	-56,401,941	7,061,790	-26,987,976
Interest (expense) income, net	-902,658	280,709	188,701
Derivative gain (loss)	121,228	-5,594,152	3,463,453
Other (expenses) income, net	-210,242	32,954	10,706
Total nonoperating Income (Expense)	-991,672	-5,280,489	3,662,860
(Loss) income before taxes	-57,393,613	1,781,301	-23,325,116
Income tax expense	'	-129,120	'
Net (loss) income attributable to common stockholders	($57,393,613)	$1,652,181	($23,325,116)
Basic:	'	'	'
Weighted average common stock shares outstanding	37,941,044	30,546,581	28,322,477
Basic earnings per share	($1.51)	$0.05	($0.82)
Diluted:	'	'	'
Diluted weighted average common stock shares outstanding	37,941,044	30,689,235	28,322,477
Diluted earnings per share	($1.51)	$0.05	($0.82)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' (Deficit) Equity (USD $)

Total

CDC Warrant [Member]

Private Placement [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Additional Paid-In Capital [Member]

Additional Paid-In Capital [Member]

Treasury Stock [Member]

Accumulated Deficit [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

CDC Warrant [Member]

Private Placement [Member]

CDC Warrant [Member]

Private Placement [Member]

Private Placement [Member]

Beginning Balance at Dec. 31, 2010

$9,786,330

'

'

$24,039

'

'

$82,055,934

'

'

($47,183)

($72,246,460)

'

'

Beginning Balance, shares at Dec. 31, 2010

'

'

'

24,038,445

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,226,724

'

'

'

'

'

1,226,724

'

'

'

'

'

'

Stock option exercise

349,676

'

'

130

'

'

349,546

'

'

'

'

'

'

Stock option exercise, shares

129,888

'

'

129,888

'

'

'

'

'

'

'

'

'

CDC warrant derivative reclassified to equity

336,747

'

'

'

'

'

336,747

'

'

'

'

'

'

Warrant exercises

'

1,749,259

'

'

601

'

'

1,748,658

'

'

'

'

'

Warrants exercises, shares

'

'

'

'

601,120

'

'

'

'

'

'

'

'

Stock offering, net

'

'

13,996,773

'

'

4,808

'

'

13,991,965

'

'

'

'

Stock offering, net shares

'

'

'

'

'

4,807,693

'

'

'

'

'

'

'

Net income (loss)

-23,325,116

'

'

'

'

'

'

'

'

'

-23,325,116

'

'

Ending Balance at Dec. 31, 2011

4,120,393

'

'

29,578

'

'

99,709,574

'

'

-47,183

-95,571,576

'

'

Ending Balance, shares at Dec. 31, 2011

'

'

'

29,577,146

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,619,269

'

'

'

'

'

1,619,269

'

'

'

'

'

'

Stock option exercise

2,054,100

'

'

789

'

'

2,053,311

'

'

'

'

'

'

Stock option exercise, shares

789,305

'

'

789,305

'

'

'

'

'

'

'

'

'

Restricted stock awards

'

'

'

58

'

'

-58

'

'

'

'

'

'

Restricted stock awards, shares

'

'

'

57,500

'

'

'

'

'

'

'

'

'

Warrant derivative liability reclassified to equity

1,037,237

'

'

'

'

'

1,037,237

'

'

'

'

'

'

Warrant exercises

921,019

'

'

282

'

'

920,737

'

'

'

'

'

'

Warrants exercises, shares

'

'

'

281,865

'

'

'

'

'

'

'

'

'

Stock offering, net

'

'

38,373,014

'

'

6,792

'

'

38,363,513

'

'

'

2,709

Stock offering, net shares

'

'

'

6,791,887

'

6,791,887

'

'

'

'

'

'

2,709,300

Net income (loss)

1,652,181

'

'

'

'

'

'

'

'

'

1,652,181

'

'

Ending Balance at Dec. 31, 2012

49,777,213

'

'

37,499

'

'

143,703,583

'

'

-47,183

-93,919,395

2,709

'

Ending Balance, shares at Dec. 31, 2012

'

'

'

37,497,703

'

'

'

'

'

'

'

2,709,300

'

Stock-based compensation

3,327,014

'

'

'

'

'

3,327,014

'

'

'

'

'

'

Stock option exercise

357,281

'

'

115

'

'

357,166

'

'

'

'

'

'

Stock option exercise, shares

115,667

'

'

115,667

'

'

'

'

'

'

'

'

'

Restricted stock awards

'

'

'

80

'

'

-80

'

'

'

'

'

'

Restricted stock awards, shares

'

'

'

80,498

'

'

'

'

'

'

'

'

'

Warrant derivative liability reclassified to equity

11,266

'

'

'

'

'

11,266

'

'

'

'

'

'

Warrant exercises

50,000

'

'

10

'

'

49,990

'

'

'

'

'

'

Warrants exercises, shares

'

'

'

10,000

'

'

'

'

'

'

'

'

'

Shares issued to Arcion in acquisition of research and development license

2,072,136

'

'

500

'

'

2,071,636

'

'

'

'

'

'

Shares issued to Arcion in acquisition of research and development license , shares

'

'

'

500,516

'

'

'

'

'

'

'

'

'

Warrants issued in connection with notes payable

986,352

'

'

'

'

'

986,352

'

'

'

'

'

'

Net income (loss)

-57,393,613

'

'

'

'

'

'

'

'

'

-57,393,613

'

'

Ending Balance at Dec. 31, 2013

($812,351)

'

'

$38,204

'

'

$150,506,927

'

'

($47,183)

($151,313,008)

$2,709

'

Ending Balance, shares at Dec. 31, 2013

'

'

'

38,204,384

'

'

'

'

'

'

'

2,709,300

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities:	'	'	'
Net (loss) income	($57,393,613)	$1,652,181	($23,325,116)
Adjustments to reconcile net (loss) income to net cash flows from operating activities	'	'	'
Depreciation	207,441	465,929	444,527
Accretion of debt discount	164,391	'	'
Amortization of intangible assets	1,139,832	1,020,878	890,980
Derivative (gain) loss	-121,228	5,594,152	-3,463,453
Stock-based compensation expense	3,327,014	1,619,269	1,226,724
Purchase of Arcion license with common stock	2,072,136	'	'
Changes in assets and liabilities:	'	'	'
Accounts receivable	-2,273,228	-419,680	530,544
Prepaid expenses and other assets	-68,928	3,822	6,226
Accounts payable and accrued expenses	-656,795	5,567,962	407,441
Income taxes payable	'	129,120	'
Deferred revenue	-6,499,838	-3,446,309	7,133
Net cash flows from operating activities	-60,102,816	12,187,324	-23,274,994
Investing activities:	'	'	'
Purchase of equipment	-76,893	-38,550	-286,973
Purchase of intangible assets	'	-1,050,000	'
Net cash flows from investing activities	-76,893	-1,088,550	-286,973
Financing activities:	'	'	'
Proceeds from sales of securities	'	38,373,014	13,996,773
Proceeds from exercise of stock options	357,281	2,054,100	349,676
Proceeds from exercise of common stock warrants	50,000	921,019	1,749,259
Proceeds from notes payable and warrants	20,000,000	'	'
Payment of deferred financing fees	-241,070	'	'
(Repayment of) proceeds from related party advances, net	'	-7,805	7,805
Net cash flows from financing activities	20,166,211	41,340,328	16,103,513
Net change in cash and cash equivalents	-40,013,498	52,439,102	-7,458,454
Cash and cash equivalents at beginning of year	63,189,307	10,750,205	18,208,659
Cash and cash equivalents at end of year	23,175,809	63,189,307	10,750,205
Cash paid for interest	742,097	'	'
Cash paid for taxes	$80,457	'	'

Nature_of_Business_and_Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Nature of Business and Summary of Significant Accounting Policies	'
	1	Nature of business and summary of significant accounting policies:
	Organization:
	BioDelivery Sciences International, Inc. (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company and its subsidiaries, Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”) are collectively referred herein to as the “Company.”
	The Company is a specialty pharmaceutical company that is leveraging its novel, proprietary and patented BioErodible MucoAdhesive (“BEMA®”) drug delivery technology to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics, primarily in the areas of pain management and oncology supportive care. The Company’s development strategy focuses on utilization of the U.S. Food and Drug Administration’s (“FDA”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved therapeutics.
	As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock”.
	Principles of consolidation:
	The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. BND is currently and has for several years been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated.
	Significant accounting policies:
	Cash and cash equivalents:
	Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company’s cash equivalents include Ultra Short Term Government Funds. Because of the short-term maturities of the Company’s cash and cash equivalents, the Company does not believe that an increase in market rates would have a significant impact on the realized value of its investments. The Company places cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $250,000 for substantially all depository accounts. The Company may from time to time have amounts on deposit in excess of the insured limits. As of December 31, 2013, the Company had approximately $22.8 million, which exceed these insured limits.
	Revenue recognition:
	The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through up-front payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 5, 6, 7 and 8.
	Meda License, Development and Supply Agreement:
	General
	The Company entered into license, development and supply agreements (collectively, the “Meda Agreements”) with Meda AB, a Swedish company (“Meda”), in September 2007 (covering the United States, Canada and Mexico) and August 2006 (covering certain countries in Europe) to develop and commercialize the Company’s sole FDA-approved and marketed product, ONSOLIS® (fentanyl buccal soluble film), a treatment with an initial indication for “breakthrough” cancer pain. ONSOLIS® is a product consisting of the narcotic fentanyl formulated with the Company’s patented BEMA® technology. The Company’s deliverables under the Meda Agreements, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 5.
	License and product development research and development services revenue
	Based on the Company’s assessment of each arrangement, all deliverables under the Meda Agreements have been accounted for as one combined unit of accounting and, as such, all cash payments from Meda (upfront payments and product development research and development services revenue) related to these deliverables were recorded as deferred revenue. Upon delivery of the license rights to Meda in October 2009, the Company recognized revenue associated with the license and the research and development services rendered related to development of the ONSOLIS® product through the date of FDA and other governmental approval. A portion of the upfront payments have been attributed to the Company’s continuing obligation to participate in joint committees with Meda and to provide certain other specified services and this revenue will be recognized as services are provided through expiration of the license agreements.
	Endo License and Development Agreement:
	General
	The Company entered into a worldwide license and development agreement (the “Endo Agreement”) with Endo Pharmaceuticals, Inc. (“Endo”) in January 2012 to develop and commercialize the Company’s product candidate BEMA® Buprenorphine. BEMA® Buprenorphine is a partial mu-opioid agonist and a potential treatment for moderate to severe chronic pain. The Company’s deliverables under the Endo Agreement, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 6.
	License and product development research and development services revenue
	Upon delivery of the license rights for BEMA® Buprenorphine to Endo in January 2012, the Company recognized revenue of $15.6 million of the $30 million non-refundable up-front license fee, with the balance of $14.4 million recorded as deferred revenue to be recognized as the related research and development services are rendered. Of the amount deferred, the Company recognized $5.2 million as revenue in 2012 and $6.3 million as revenue in 2013. In addition, in May 2012 the Company received and recognized $15 million in revenue associated with an intellectual property milestone under the Endo Agreement.
	Arcion License Agreement:
	General
	The Company entered into a definitive exclusive license agreement (the “Arcion Agreement”) with Arcion in March 2013 pursuant to which Arcion agreed to grant to the Company an exclusive commercial world-wide license, with rights of sublicense, under certain patent and other intellectual property rights related to in-process research and development to develop, manufacture, market, and sell gel products containing clonidine (or a derivative thereof), alone or in combination with other active ingredients, for topical administration for the treatment of painful diabetic neuropathy and other indications (the “Arcion Products”). The Arcion Agreement, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 7.
	Upon receipt of the license rights for clonidine from Arcion in March 2013, the Company made a payment to Arcion of $2.1 million in unregistered Common Stock in exchange for in-process research and development that has been recorded as research and development expense for the year ended December 31, 2013. The Company is also responsible for using commercially reasonable efforts to develop and commercialize Arcion Products, including the use of such efforts to conduct certain clinical trials within certain time frames.
	Contract Revenue
	The Company earned contract revenue as a result of Meda up-front and milestone payments related to ONSOLIS®. Upon FDA approval of ONSOLIS® in July 2009, and the subsequent commercial launch of ONSOLIS® in October 2009, the Company recognized this contract revenue. The Company also recognized contract revenue as a result of the approval and subsequent launch of BREAKYL™ in the E.U. in 2012.
	The Company also earned contract revenue related to two similar license, development and supply agreements covering different territories: (i) Kunwha Pharmaceutical Co., Ltd., a Republic of Korea corporation (“Kunwha”), to develop, manufacture, sell and distribute BEMA® Fentanyl in the Republic of Korea, and (ii) TTY Biopharm Co., Ltd., a Taiwanese company (“TTY”), to develop, manufacture, sell and distribute the Company’s BEMA® Fentanyl product in Taiwan. Upfront payments from Kunwha and TTY are recorded as contract revenue upon receipt. The Company earned contract revenues in 2011 and 2013 related to milestones from TTY upon government approvals.
	Research and Development Reimbursements
	The Company is reimbursed by Endo for certain contractor costs when these costs go beyond set thresholds as outlined in the License and Development Agreement dated January 5, 2012 between the Company and Endo. Endo reimburses the Company for this spending at cost and the Company receives no mark-up or profit. The gross amount of these reimbursed research and development costs are reported as revenue in the accompanying consolidated statements of operations. The Company acts as a principal, has discretion to choose suppliers, bears credit risk and may perform part of the services required in the transactions. Therefore, these reimbursements are treated as revenue to the Company. The actual expenses creating the reimbursements are reflected as research and development expense.
	Cost of Product Royalties
	The cost of product royalties includes the direct costs attributable to the production of ONSOLIS® and BREAKYL™. It includes all costs related to creating the product at the Company’s contract manufacturing locations in the U.S. and Germany. The Company’s contract manufacturers bill the Company for the final product, which includes materials, direct labor costs, and certain overhead costs as outlined in applicable supply agreements. Cost of product royalties also includes royalty expenses that the Company owes to third parties.
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.
	Certain Risks, Concentrations and Uncertainties
	The Company’s product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates that have not yet been so approved, there is a risk that they will not receive necessary approval. If approval is denied or delayed, it may have a material adverse impact on the Company. In addition, the Company’s products compete in rapidly changing, highly competitive markets which are characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements and developing industry standards. Any failure by the Company to anticipate or to respond adequately to scientific developments, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company’s business, operating results and future cash flows.
	Accounts receivable from one customer (Endo) accounted for 99.6% and from another customer (Meda) accounted for 83% of the Company’s trade accounts receivable at December 31, 2013 and December 31, 2012, respectively. Deferred revenue balances relate to the Meda and Endo Agreements at December 31, 2013 and 2012. The Company depends significantly upon the collaboration with Meda and Endo, and its activities may be impacted if these relationships are disrupted.
	Key components used in the manufacture of ONSOLIS® are currently provided by a sole or a limited number of suppliers. This could result in the Company’s inability to timely obtain an adequate supply of required components and reduce control over pricing, quality and timely delivery. Also, if the supply of any components is interrupted, components from alternative suppliers may not be available in sufficient volumes within required time frames, if at all, to meet the Company’s obligations under the Meda supply agreements. This could delay timely commercialization efforts by Meda, causing the Company to lose royalty revenue and potentially harming its reputation.
	Deferred revenue
	Consistent with the Company’s revenue recognition policy, deferred revenue represents cash received in advance for licensing fees, consulting, research and development services and related supply agreements. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date.
	Equipment
	Office and manufacturing equipment are carried at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to ten years.
	Due to the postponement of the U.S. re-launch of ONSOLIS® (note 5), related manufacturing equipment, net, totaling $2.8 million has been deemed idle, and has been reclassified to idle equipment, net in the accompanying consolidated balance sheet as of December 31, 2013. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has not recorded any impairment of this equipment during the year ended December 31, 2013 because; (i) the Company believes that the equipment will be utilized again once ONSOLIS® is re-launched and (ii) the equipment will be used in the manufacturing of BUNAVAIL™ if approved by the FDA.
	Intangibles and Goodwill
	The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its long-lived assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.
	There was no impairment charges recognized on finite lived intangibles in 2013, 2012 or 2011.
	Intangible assets with finite useful lives are amortized over the estimated useful lives as follows:
			Estimated
			Useful Lives
	Licenses		15 years
	U.S. Product rights		10-12 years
	EU Product rights		11 years
	The Company incurred amortization expense on other intangible assets of approximately $1.0 million, $1.0 million and $0.9 million for the years ended December 31, 2013, 2012 and 2011, respectively. Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows:
	Years ending December 31,
	2014		$	970,356
	2015			970,356
	2016			970,356
	2017			970,356
	2018			970,356
	Thereafter			344,718
			$	5,196,498
	Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. In the course of the evaluation of the potential impairment of Goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether impairment has occurred, a quantitative evaluation is performed. The quantitative impairment analysis involves a two-step process. Step one involves the comparison of the fair value of the reporting unit to which goodwill relates (the Company’s enterprise value) to the carrying value of the reporting unit. If the fair value exceeds the carrying value, there is no impairment. If the carrying value exceeds the fair value of the reporting unit, the Company determines the implied fair value of goodwill and records an impairment charge for any excess of the carrying value of goodwill over its implied fair value. There were no goodwill impairment charges in 2013, 2012 or 2011.
Use of estimates in financial statements:
The preparation of the accompanying consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.
Net (loss) income per common share:
The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2013, 2012 and 2011.
		December 31,
		2013			2012		2011
Basic:
Net (loss) income attributable to common stockholders		$	(57,393,613	)	$	1,652,181	$	(23,325,116	)
Weighted average common shares outstanding			37,941,044			30,546,581		28,322,477
Basic earnings per common share		$	(1.51	)	$	0.05	$	(0.82	)
Diluted:
Effect of dilutive securities:
Net (loss) income attributable to common stockholders			(57,393,613	)		1,652,181		(23,325,116	)
Adjustments to income for dilutive options and warrants			—			—		—
			(57,393,613	)		1,652,181		(23,325,116	)
Weighted average common shares outstanding			37,941,044			30,546,581		28,322,477
Effect of dilutive options and warrants			—			142,654		—
Diluted weighted average common shares outstanding			37,941,044			30,689,235		28,322,477
Diluted earnings per common share		$	(1.51	)	$	0.05	$	(0.82	)
Basic earnings per common share is calculated using the weighted average shares of Common Stock outstanding during the period. Common equivalent shares from stock options and warrants using the treasury stock method, are also included in the diluted per share calculations unless the effect of inclusion would be antidilutive. During the years ended December 31, 2013, 2012 and 2011, outstanding stock options and warrants of 6,549,719, 5,509,075 and 7,847,052, respectively, were not included in the computation of diluted earnings per common share, because to do so would have had an antidilutive effect because the outstanding exercise prices were greater than the average market price of the common shares during the relevant periods.
Stock-based compensation:
The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The fair value of each option and warrant is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common
Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield.
In applying the Black Scholes options-pricing model, assumptions are as follows:
		2013		2012	2011
Expected price volatility		77.59%-81.65%		81.96%-83.69%	69.05%-77.75%
Risk-free interest rate		0.70%-1.60%		0.62%-1.02%	0.90%-1.99%
Weighted average expected life in years		5-6 years		5-6 years	5-6 years
Dividend yield		—		—	—
Fair Value of Financial Assets and Liabilities
The Company measures the fair value of financial assets and liabilities in accordance with generally accepted accounting principles of the United States (“GAAP”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Derivative instruments:
The Company generally does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain other financial instruments and contracts, such as debt financing arrangements and freestanding warrants with features that are either not afforded equity classification, embody risks not clearly and closely related to host contracts, or may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value, in the Company’s consolidated financial statements.
The Company estimates fair values of derivative financial instruments using the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fairly value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the Company’s trading market price which has high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company’s income will reflect the volatility in these estimate and assumption changes.
Recent accounting pronouncements:
In July 2012, the FASB issued ASU 2012-02 – Testing Indefinite-Lived Intangible Assets for Impairment (“ASU 2012-02”) in order to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance. The new guidance allows an entity the option to make a qualitative assessment about the likelihood that an indefinite-lived intangible asset is impaired to determine whether it should perform a quantitative impairment test. ASU 2012-02 was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012 and early adoption was permitted.
The Company adopted this standard on January 1, 2013. The adoption of this standard had no material impact on the Company’s consolidated financial statements.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Liquidity and Management's Plans	'
	2	Liquidity and management’s plans:
	Since inception, the Company has financed its operations principally from the sale of equity securities, proceeds from short-term borrowings or convertible notes, funded research arrangements and revenue generated as a result of its worldwide license and development agreement with Meda regarding ONSOLIS® and revenue generated as a result of its January 2012 agreement with Endo regarding its BEMA® Buprenorphine product candidate. The Company intends to finance its research and development and commercialization efforts and its working capital needs from existing cash, royalty revenue, new sources of debt and equity financing, existing and new licensing and commercial partnership agreements and, potentially, through the exercise of outstanding Common Stock options and warrants to purchase Common Stock.
	Significant new financing and operating sources during the year ended December 31, 2013 consisted of:
		•	approximately $19.8 million in net proceeds from secured loan facility from MidCap Financial SBIC, LP, as agent and lender (“MidCap”) (See note 9);
		•	approximately $2.8 million in research and development reimbursements under the Endo agreement;
		•	approximately $1.8 million in net royalties under the Meda agreements;
		•	approximately $0.3 million in contract revenue from licensing and supply agreement (see note 8); and
		•	approximately $0.4 million from the exercise of stock options and warrants.
	Significant new financing and operating sources during the year ended December 31, 2012 consisted of:
		•	approximately $45 million in upfront and milestone payments from the Endo license agreement (see note 6);
		•	approximately $38.4 million in net proceeds from a registered direct offering of Common Stock and newly designated Series A Non-Voting Convertible Preferred Stock, par value $.001 per share (the “Series A Preferred”) in November 2012;
		•	approximately $17.5 million in contract revenue from the Meda license agreement. (see note 5);
		•	approximately $2.1 million from the exercise of stock options; and
		•	approximately $0.9 million from the exercise of Common Stock warrants.
	Significant financing and operating sources during the year ended December 31, 2011 consisted of:
		•	approximately $14 million in net proceeds from a private placement offering of Common Stock in March 2011;
		•	approximately $1 million in net royalties;
		•	approximately $1.7 million from the exercise of Common Stock warrants;
		•	approximately $0.3 million in contract revenue from licensing and supply agreement (see note 8);
		•	approximately $0.2 million in research revenues from various contractor agreements; and
		•	approximately $0.3 million from the exercise of Common Stock options.
	On July 5, 2013, the Company, together with Arius One and Arius Two, entered into a $20 million secured loan facility pursuant to a Credit and Security Agreement (the “Credit Agreement”) with MidCap. The Company received net proceeds in the aggregate amount of $19.8 million and is using the loan proceeds for general corporate purposes or other activities permitted under the Credit Agreement. (See note 9).
	In November 2013, the Company filed a shelf registration statement which registered up to $75 million of the Company’s securities for potential future issuance, and such registration statement was declared effective on December 18, 2013. Concurrently with the filing of such registration statement, the Company established an “at-the-market” offering program utilizing the universal shelf registration for up to $15 million of common stock. Cantor Fitzgerald & Co. is the placement agent for such offering program. In January 2014, the Company sold 658,489 shares of common stock under such offering program for approximate gross proceeds of $4 million.
	On January 23, 2014, the Company announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA® Buprenorphine in opioid-“naive” subjects. The locking of the database for the opioid naive study has triggered a $10 million milestone payment from Endo per the Company’s licensing agreement. Such payment was received in February, 2014.
	In December 2013 and January and February of 2014, a warrant holder exercised an aggregate of 10,000 and 515,000 shares of common stock underlying a warrant for proceeds to the Company of $0.05 million and $2.6 million, respectively.
	From January through March 2014, Company employees and directors exercised approximately 0.7 million stock options, which net proceeds to the Company was $2.2 million.
	On February 7, 2014, the Company entered into a definitive Securities Purchase Agreement with certain institutional investors relating to a registered direct offering by the Company of 7,500,000 shares of the Company’s common stock, par value $.001 per share. The shares were sold at a price of $8.00 per share, yielding gross offering proceeds of $60 million. The offering price per share was determined based on an approximately 3.1% discount to the closing price of the Common Stock on February 7, 2014.
	At December 31, 2013, the Company had cash and cash equivalents of approximately $23.2 million. The Company used $60.1 million of cash from operations during the twelve months ended December 31, 2013. As of December 31, 2013, the Company had stockholders’ (deficit) equity of $(0.8) million, versus $49.8 million at December 31, 2012. The Company’s existing cash, together with other expected cash inflows from other milestones and royalties, are anticipated by management to be sufficient to fully fund the Company’s operations through the second quarter of 2015.
	Additional capital may be required to support commercialization activities for BUNAVAIL™, clinical development programs for BEMA® Buprenorphine (the scale of which is being governed in large part by the requirements of our agreement with Endo), the reformulation project for and anticipated commercial relaunch of ONSOLIS®, planned development of Clonidine Topical Gel produced for painful diabetic neuropathy and general working capital. Based on product development timelines and agreements with our development partners, the ability to scale up or reduce personnel and associated costs are factors considered throughout the product development life cycle. Available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding.

Research_and_Development_Arran

Research and Development Arrangements and Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Research and Development Arrangements and Related Party Transactions	'
	3	Research and development arrangements and related party transactions:
	In June 2012, the Company entered into an agreement to terminate its license agreement with the University of Medicine and Dentistry of New Jersey (“UMDNJ”) and certain sublicenses related to the Bioral® drug delivery technology previously developed by the Company under such license. Under this agreement, the Company agreed to assign to UMDNJ its know-how to the Bioral® technology. All sublicenses related to the Bioral® technology have been formally terminated, and the Company has assigned to UMDNJ its know-how and patent rights to the Bioral® technology in consideration of 10% of future potential revenues collected by UMDNJ for commercialization of Bioral® formulated Amphotericin B products and 3.5% for non-Bioral® formulated Amphotericin B products which utilize such patent rights and know-how. We have not earned any revenue from UMDNJ on commercialization of the aforementioned products during 2013 or 2012.
	Previously, the Company rented office space for accounting and administrative staff in Tampa, Florida from Accentia Biopharmaceuticals, Inc., a former related party (“Accentia”), and shared one employee, with personnel costs paid based on the approximate time spent on Company activities. Rent payments to Accentia were $0.03 million for year ended 2013 and $0.06 million for years 2012 and 2011, respectively, and are included in general and administrative costs, related party.
	In 2009, as part of a settlement arrangement, the Company received a warrant from Accentia, a former related party, to purchase two million shares of common stock of Biovest International, Inc. (“Biovest”) held by Accentia. Biovest was a majority-owned subsidiary of Accentia. During the year ended December 31, 2013, Biovest filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court. On July 9, 2013, the plan became effective, which canceled all outstanding common stock and warrants. As a result, the warrants had no value as of December 31, 2013 and the reduction of value is included in derivative gain (loss) in the consolidated statement of operations for the year ended December 31, 2013.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Equipment	'
	4	Equipment:
	Equipment consists of the following:
			December 31,
			2013			2012
	Office and laboratory equipment		$	4,761,418		$	4,366,797
	Less accumulated depreciation			(1,738,532	)		(1,531,090	)
			$	3,022,886		$	2,835,707
	Less idle equipment			(2,844,718	)		—
			$	178,168		$	2,835,707
	Depreciation expense for years ended December 31, 2013, 2012 and 2011 was approximately $0.2 million, $0.5 million and $0.4 million, respectively.

Meda_License_Development_and_S

Meda License, Development and Supply Agreements	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Meda License, Development and Supply Agreements	'
	5	Meda License, Development and Supply Agreements:
	In August 2006 and September 2007, the Company entered into certain agreements with Meda to develop and commercialize the ONSOLIS® product, a drug treatment for breakthrough cancer pain delivered utilizing the BEMA® technology. The aforementioned agreements relate to the United States, Mexico and Canada (such agreements, the “Meda U.S. Agreements”) and to certain countries in Europe (such agreements, the “Meda EU Agreements”, together with Meda U.S. Agreements, the “Meda Agreements”). They carry license terms that commence on the date of first commercial sale in each respective territory and end on the earlier of the entrance of a generic product to the market or upon expiration of the patents, which begin to expire in 2020.
	The Company determined that upon inception of both the U.S. and EU Meda arrangements all deliverables are to be considered one combined unit of accounting since the fair value of the undelivered license was not determinable and the research and development efforts provided do not have stand-alone value apart from the license. As such, all cash payments from Meda that were related to these deliverables were recorded as deferred revenue. Upon commencement of the license term (date of first commercial sale in each territory), the license and certain deliverables associated with research and development services were deliverable to Meda. The first commercial sale in the U.S. occurred in October 2009. As a result, $59.7 million of the aggregate milestones and services revenue was recognized as revenue. The first commercial sale in a European country occurred in October 2012. As a result, $17.5 million was recognized as revenue, which included $5.0 million in milestones received during the year ended December 31, 2012. At December 31, 2013, there was remaining deferred revenue of $1.3 million which is related to the Meda research and development services. As time progresses, the Company will continue to estimate the time required for ongoing obligations, and adjust the remaining deferred revenue accordingly on a quarterly basis.
	The Company earns royalties based on a percentage of net sales revenue of the ONSOLIS® product. The Company earned $1.8 million and $1.1 million in product royalty revenue for the years ended December 31, 2013 and 2012, respectively. The Company has incurred cost of product royalties of approximately $2.1 million and $1.9 million for the years ended December 31, 2013 and 2012, respectively, which included minimum royalty expenses that the Company is obligated to pay CDC IV, LLC (“CDC”) and NB Athyrium LLC (“Athyrium”) regardless of actual sales.
	Upon delivery of the license to Meda, the Company determined that each of the undelivered obligations had stand-alone value to Meda as these post-commercialization services encompass additional clinical trials on different patient groups but do not require further product development and these services and product supply obligations can be provided by third-party providers available to Meda. The Company also obtained third-party evidence of fair value for the other research and development services and other service obligations, based on hourly rates billed by unrelated third-party providers for similar services contracted by the Company. The Company has obtained third-party evidence of fair value of the product supply deliverable based on the outsourced contract manufacturing cost charged to the Company from the third-party supplier of the product. The arrangements do not contain any general rights of return. Therefore, the remaining deliverables to the arrangements have been accounted for as three separate units of accounting to include (1) product supply, (2) research and development services for the ONSOLIS® product and (3) the combined requirements related to the remaining other service-related obligations due Meda to include participation in committees and certain other specified services. The estimated portion of the upfront payments of approximately $1.2 million (under the Meda U.S. Agreements) and $0.1 million (under the Meda EU Agreements) attributed to these other service-related obligations will be recognized as revenue as services are provided through expiration of the license terms, as defined above.
	The Company has determined that it is acting as a principal under the Meda Agreements and, as such, will record product supply revenue, research and development services revenue and other services revenue amounts on a gross basis in the Company’s consolidated financial statements.
	On March 12, 2012, the Company announced the postponement of the U.S. re-launch of ONSOLIS® following the initiation of the class-wide REMS until the product formulation could be modified to address two appearance-related issues raised by FDA during an inspection of the manufacturing facility of the Company’s North American manufacturing partner for ONSOLIS®, Aveva Drug Delivery Systems, Inc. (“Aveva”). Specifically, the FDA identified the formation of microscopic crystals and a fading of the color in the mucoadhesive layer during the 24-month shelf life of the product. While these changes do not affect the product’s underlying integrity, safety or performance, the FDA believes that the fading of the color in particular may potentially confuse patients, necessitating a modification of the product and product specification before additional product can be manufactured and distributed.
	The source of microcrystal formation and the potential for fading of the product was found to be specific to a buffer used in the manufacturing process for ONSOLIS®. ONSOLIS® has been reformulated and the Company’s believes the appearance issues have been resolved. Meda, the Company’s commercial partner, is working to determine the content and timing of the submission to FDA. Once submitted, FDA’s review of the application may take up to 6 months. If the submission is made before mid-2014, and approved by FDA, the relaunch could occur by years end, otherwise, the relaunch would move to sometime 2015.
	On May 21, 2012, the Company announced receipt of a pre-launch milestone payment of $2.5 million from Meda in conjunction with the first country registration and pricing approval for BREAKYL™ (tradename for ONSOLIS®in the EU). A final milestone payment related to the EU of $2.5 million was paid at the time of commercial launch, which occurred in October 2012. BREAKYL™ is commercialized in the EU by Meda.
	On September 13, 2012, the Company executed a Manufacturing, Supply, and License Agreement, effective April 26, 2012, with LTS Lohmann Therapie-Systeme AG (“LTS”), under which LTS will manufacture and supply the Company its BREAKYL™ product for distribution outside of the U.S. and Canada. The Company is required to supply BREAKYL™ product to Meda, Kunwha and TTY pursuant to its obligations under certain license and supply agreements under which Meda, Kunwha, and TTY develop and commercialize the BREAKYL™ product. In conjunction with the agreement, LTS has waived all royalties on products that they produce. This does not preclude royalties that the Company owes to LTS if the Company produces BREAKYL™ with another company.

Endo_License_and_Development_A

Endo License and Development Agreement	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Endo License and Development Agreement	'
	6	Endo License and Development Agreement:
	In January 2012, the Company entered into a License and Development Agreement (the “Endo Agreement”) with Endo pursuant to which the Company granted to Endo an exclusive commercial world-wide license to develop, manufacture, market and sell the Company’s BEMA® Buprenorphine product and to complete U.S. development of such product candidate for purposes of seeking FDA approval.
	Pursuant to the Endo Agreement, Endo has obtained all rights necessary to complete the clinical and commercial development of BEMA® Buprenorphine and to sell the product worldwide. Although Endo has obtained all such necessary rights, the Company has agreed under the Endo Agreement to be responsible for the completion of certain clinical trials regarding BEMA® Buprenorphine (and providing clinical trial materials for such trials) necessary to submit a NDA to the FDA in order to obtain approval of BEMA® Buprenorphine in the U.S., in each case pursuant to a development plan set forth in the Endo Agreement (as it may be amended pursuant to the Endo Agreement). The Company is responsible for development activities through the filing of the NDA in the U.S., while Endo is responsible for the development following the NDA submission as well as the manufacturing, distribution, marketing and sales of BEMA® Buprenorphine on a worldwide basis. In addition, Endo is responsible for all filings required in order to obtain regulatory approval of BEMA® Buprenorphine.
	Pursuant to the Endo Agreement, the Company has received (or is expected to receive upon satisfaction of applicable conditions) the following payments (some portion(s) of which will be utilized by the Company to support its development obligations under the Endo Agreement with respect to BEMA® Buprenorphine):
		•	$30 million non-refundable upfront license fee (received January 17, 2012);
		•	up to an aggregate of $95 million in six separate potential milestone payments based on the following pre-defined events: (i) enhancement of intellectual property rights (two milestones aggregating $35 million in potential milestone payments, including $15 million upon issuance of a certain patent covering the product, which was received May 2012), (ii) clinical development (two milestones aggregating $20 million in potential milestone payments) and (iii) regulatory events (two milestones aggregating $40 million in potential milestone payments);
		•	up to an aggregate of $55 million based on the achievement of four separate post-approval sales thresholds; and
		•	sales-based royalties in a particular percentage range on U.S. sales of BEMA® Buprenorphine, and royalties in a lesser range on sales outside the United States, subject to certain restrictions and adjustments.
	The Company has assessed its arrangement with Endo and the Company’s deliverables thereunder at inception to determine: (i) the separate units of accounting for revenue recognition purposes, (ii) which payments should be allocated to which of those units of accounting and (iii) the appropriate revenue recognition pattern or trigger for each of those payments. The assessment requires subjective analysis and requires management to make judgments, estimates and assumptions about whether deliverables within multiple-element arrangements are separable and, if so, to determine the amount of arrangement consideration to be allocated to each unit of accounting.
	At the inception of the Endo arrangement, the Company determined that the Endo Agreement is a multi-deliverable arrangement with three deliverables: (1) the license rights related to BEMA® Buprenorphine, (2) services related to obtaining
	enhanced intellectual property rights through the issuance of a particular patent and (3) clinical development services. The Company concluded that the license delivered to Endo at the inception of the Endo Agreement has stand-alone value because Endo obtained, at the inception of the Endo Agreement, all of the rights and knowledge necessary to fully exploit its license without the Company’s further involvement. It was also determined that there was a fourth deliverable, the provision of clinical trial material (“CTM”). The amounts involved are, however, immaterial and delivered in essentially the same time frame as the clinical development services. Accordingly, the Company has not separately accounted for the CTM deliverable, but considers it part of the clinical development services deliverable.
	The initial non-refundable $30 million license fee was allocated to each of the three deliverables based upon their relative selling prices using best estimates. The analysis of the best estimate of the selling price of the deliverables was based on the income approach, the Company’s negotiations with Endo and other factors, and was further based on management’s estimates and assumptions which included consideration of how a market participant would use the license, estimated market opportunity and market share, the Company’s estimates of what contract research organizations would charge for clinical development services, the costs of clinical trial materials and other factors. Also considered were entity specific assumptions regarding the results of clinical trials, the likelihood of FDA approval of the subject product and the likelihood of commercialization based in part on the Company’s prior agreements with the BEMA® technology.
	Based on this analysis, $15.6 million of the up-front license fee was allocated to the license (which was estimated to have a value significantly in excess of $30 million), and $14.4 million to clinical development services (which is inclusive of the cost of CTM). Although the intellectual property component was considered a separate deliverable, no distinct amount of the up-front payment was assigned to this deliverable because the Company determined the deliverable to be perfunctory. In April 2012, the patent being sought by the Company was granted as described further below, and in May 2012, the applicable intellectual property milestone payment of $15 million was received and recognized as revenue. The amount allocated to the license was recognized as revenue in January 2012.
	The portion of the upfront license fee allocated to the clinical development services deliverable ($14.4 million) is being recognized as those services are performed. The Company estimates that such clinical development services will extend into the first half of 2015. Based on the estimated proportion of those services performed through December 31, 2013, $5.2 million was recognized as revenue in fiscal year 2012 and $6.3 million was recognized as revenue in fiscal year 2013. As a result, $2.9 million remains deferred at December 31, 2013.
	The Company analyzed the milestone payments noted above to determine if such milestones are substantive. This determination included an analysis of the Company’s performance to achieve each milestone, the enhancement of value of the delivered items, the timing of performance related to the milestone, and the reasonability of the milestone relative to all the deliverables and payment terms. The Company concluded that each of the milestones is substantive.
	The term of the Endo Agreement shall last, on a country-by-country basis, until the later of: (i) 10 years from the date of the first commercial sale of BEMA® Buprenorphine in a particular country or (ii) the date on which the last valid claim of the Company’s patents covering BEMA® Buprenorphine in a particular country has expired or been invalidated. The Endo Agreement shall be subject to termination: (i) by Endo, at any time, upon a specific amount of prior written notice to the Company, (ii) by Endo and the Company upon mutual written agreement, (iii) by either party upon a material default or breach of the Endo Agreement and such default or breach is not cured within a specified timeframe, (iv) the voluntary or involuntary bankruptcy of either party or (v) by the Company if Endo does not meet certain diligence obligations outside of the United States.
	On February 16, 2012, the Company announced that the U.S. Patent and Trademark Office issued a Notice of Allowance regarding its patent application (No. 13/184306), which patent will extend the exclusivity of the BEMA®drug delivery technology for the Company’s BEMA® Buprenorphine and BUNAVAILTM product candidates from 2020 to 2027. On April 17, 2012, the Company announced that this patent was granted. As a result, pursuant to the Endo Agreement, the Company received a milestone payment from Endo in the amount of $15 million in May 2012. As discussed above, this milestone had been evaluated to be a substantive milestone, and therefore was recognized as revenue when the milestone was received.
	The remaining milestone payments are expected to be recognized as revenue as and if they are achieved, except that one milestone is contingently refundable for a period of time. Revenue related to that milestone is expected to be recognized as refund provisions as defined in the agreement expire. Sale threshold payments and sales-based royalties will be recognized as they accrue under the terms of the Endo Agreement.
	On January 23, 2014, the Company announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA® Buprenorphine in opioid-“naive” subjects. The locking of the database for the opioid naive study has triggered a $10 million milestone payment from Endo per the Company’s licensing agreement that was received during February, 2014.

Arcion_License_Agreement

Arcion License Agreement	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Arcion License Agreement	'
	7	Arcion License Agreement:
	On March 26, 2013, the Company entered into a definitive Exclusive License Agreement (the “Arcion Agreement”) with Arcion pursuant to which Arcion agreed to grant to the Company an exclusive commercial world-wide license, with rights of sublicense, under certain patent and other intellectual property rights related to in-process research and development to develop, manufacture, market, and sell gel products containing clonidine (or a derivative thereof), alone or in combination with other active ingredients, for topical administration for the treatment of painful diabetic neuropathy and other indications (the “Arcion Products”).
	Pursuant to the Arcion Agreement, the Company is responsible for using commercially reasonable efforts to develop and commercialize Arcion Products, including the use of such efforts to conduct certain clinical trials within certain time frames.
	Upon execution of the Arcion Agreement, the Company issued to Arcion 500,516 unregistered shares of Common Stock (having a fair market value of $2.1 million), which shares are subject to a nine month lock-up and certain limitations on sale thereafter. The issuance of such shares (delivered April 2013) was exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(2) thereof. In addition, the Company is required to make the following payments to Arcion:
		•	$2.5 million upon filing and acceptance by the FDA of an NDA with respect to an Arcion Product, payable at the Company’s option, in cash or unregistered shares of Common Stock (with such shares also being subject to a nine month lock-up and certain limitations on sale thereafter); and
		•	up to a potential $60 million in cash payments upon achieving certain pre-determined sales thresholds in the U.S., none of which occur prior to achieving at least $200 million in U.S. net sales.
	In addition, the Company shall pay Arcion $35 million in cash on initial FDA approval of an Arcion Product, unless; (i) the Company does not receive at least $70 million in FDA approval-related milestone payments from its US sublicensees (if any sublicenses are involved) with respect to the Arcion Product, in which case the Company shall pay Arcion a prorated amount between $17.5 million and $35 million based on the total amount of such milestone payments received by the Company and its affiliates from its sublicenses (if any sublicenses are involved); or (ii) the FDA requires or recommends the performance of a capsaicin challenge test as a precondition or precursor to the prescribing of the Arcion Product (as a condition of approval, a labeling requirement, or otherwise), in which case such milestone shall be reduced to $17.5 million, but the first and second sales threshold payments described above shall each be increased by $8 million.
	All milestone payments due Arcion under the Arcion Agreement are payable only once each.
	In addition to the milestones set forth above, the Company will pay Arcion:
		•	a low single digit royalty on the Company’s and its affiliates’ net sales of Arcion Products in the U.S.;
		•	a low double digit percentage of all sales-based payments received by the Company and its affiliates with respect to sublicensees’ sales of Arcion Products in the U.S.;
		•	a low single digit royalty on all net sales of Arcion Products outside the U.S.; and
		•	a low double digit percentage of all milestone payments received by the Company and its affiliates from their sublicensees that are triggered by the receipt of regulatory approval of the Arcion Product in certain jurisdictions outside of the U.S.
	The aforementioned sales royalties are subject to certain reductions, on a country-by-country and product-by-product basis, under certain agreed upon circumstances. In addition, in the event the amount due upon FDA approval of the Arcion Product in the U.S. is less than $35 million for any reason other than an FDA requirement or recommendation of a capsaicin challenge test, as described above, the Company shall pay Arcion a portion of any milestone payments received by the Company and its affiliates from their sublicensees on the basis of any events occurring in the U.S. following FDA approval but prior to (and
	including) first commercial sale of an Arcion Product in the U.S., and certain of the payments to Arcion referred to above shall also be subject to upward adjustment (with such upward adjustments payable in the form of cash or unregistered shares of the Company’s Common Stock, as elected solely by the Company), until such time as the sum of all such additional payments and upward adjustments (including the value of any issuances of stock, if elected by the Company) and the initial amount paid on the initial FDA approval totals $35 million.
	The term of the Arcion Agreement continues, on a country-by-country and product-by-product basis, until the earlier of (i) the expiration of the royalty term for a particular Arcion Product in a particular country or (ii) the effective date of termination by either party pursuant to customary termination provisions. The royalty term for any given country is the later of (i) the first date there are no valid claims against any Arcion patent, (ii) expiration of patent exclusivity or (iii) tenth anniversary of the first commercial sale. Further, the Company may, in its sole discretion, terminate the Arcion Agreement upon certain notice to Arcion. Upon expiration of the Agreement pursuant to clause (i) above with respect to a particular Arcion Product and country, the Company and its affiliates shall have the perpetual, unrestricted, irrevocable, fully-paid, royalty-free exclusive right, with rights of sublicense, to make, have made, use, sell, offer for sale, and import such Arcion Product in such country.
	In conjunction with this transaction, the March 2013 payment to Arcion of $2.1 million in unregistered Common Stock was for in-process research and development and has been recorded as research and development expense in the consolidated statement of operations for the year ended December 31, 2013.

Other_License_Agreements_and_A

Other License Agreements and Acquired Product Rights	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other License Agreements and Acquired Product Rights	'
	8	Other license agreements and acquired product rights:
	Kunwha License Agreement
	In May 2010, the Company entered into a License and Supply Agreement (the “Kunwha License Agreement”) with Kunwha to develop, manufacture, sell and distribute the Company’s BEMA® Fentanyl product in the Republic of Korea (the “Kunwha Territory”). BEMA® Fentanyl is marketed as ONSOLIS® in North America. The Kunwha License Agreement is for a term beginning on May 26, 2010 until the date of expiration of the patents, or July 23, 2027, whichever is later.
	Under the terms of the Kunwha License Agreement, Kunwha was granted exclusive licensing rights for BEMA® Fentanyl in the Kunwha Territory, while the Company will retain all other licensing rights to the Licensed Product not previously granted to third parties. Kunwha paid to the Company an upfront payment of $0.3 million (net of taxes approximating $0.25 million) and will be responsible to make certain milestone payments which could aggregate up to $1.3 million (net of taxes approximating $1.1 million). In addition, Kunwha will pay royalties to the Company based on Net Sales (as defined in the Kunwha License Agreement) and will purchase all supplies of BEMA® Fentanyl from the Company.
	Kunwha will be responsible for payment of all costs associated with BEMA® Fentanyl in the Kunwha Territory. Kunwha and the Company will own any Improvements (as defined in the Kunwha License Agreement) made exclusively by such party with respect to BEMA® Fentanyl and will jointly own any Improvements that are the product of collaboration.
	TTY License and Supply Agreement
	On October 7, 2010, the Company announced a license and supply agreement with TTY for the exclusive rights to develop and commercialize BEMA® Fentanyl in the Republic of China, Taiwan. The agreement results in potential milestone payments to the Company of up to $1.3 million, which includes an upfront payment of $0.3 million that was received in 2010. In addition, the Company will receive an ongoing royalty based on net sales. TTY will be responsible for the regulatory filing of BEMA® Fentanyl in Taiwan as well as future commercialization in that territory. The term of the agreement with TTY is for the period from October 4, 2010 until the date fifteen (15) years after first commercial sale unless the agreement is extended in writing or earlier terminated as provided for in the agreement.
	On November 7, 2011, the Company announced that TTY had submitted a New Drug Application (“NDA”) for marketing authorization of BEMA® Fentanyl to the Taiwan Food and Drug Administration. This triggered a milestone payment to the Company of approximately $0.3 million, which was received November 2011 and recorded as contract revenue in the accompanying consolidated statements of operations for the year ended December 31, 2011.
	On July 29, 2013, the Company announced the regulatory approval of BEMA® Fentanyl in Taiwan, where the product will be marketed under the brand name PAINKYL™. The approval in Taiwan resulted in a milestone payment of $0.3 million to the Company, which was received in the third quarter 2013, and recorded as contract revenue in the accompanying consolidated statement of operations for the year ended December 31, 2013.
	Agreement with Tolmar to Purchase BEMA® Rights
	In September 2007, the Company purchased all North American (U.S., Canada and Mexico) assets related to the BEMA® drug delivery technology from TOLMAR Therapeutics, Inc (“Tolmar”) for $7 million, consisting of $3 million in cash and a promissory note of $4 million, $2 million of which was paid in July 2009 following approval of ONSOLIS® in the U.S., and $2 million of which is due within thirty (30) days of the end of the calendar quarter during which cumulative net sales of BEMA®-based products reach $30 million. To secure the Company’s obligation to pay the remaining $2 million amount when due, Tolmar was granted a security interest in the North American BEMA® assets, subject to a license of those assets from Tolmar to us for North America that would be granted to us on the original license terms upon any exercise of rights under such security interest.
	On January 5, 2012, the Company and Arius Two executed a letter agreement with Tolmar and its parent company, TOLMAR Holding, Inc., whereby the parties agreed that, if Arius Two paid Tolmar $1.05 million by February 28, 2012, Tolmar would accept such payment as satisfaction in full of the remaining $2 million outstanding under the Tolmar note (pursuant to which the Company acquired the North American rights to the BEMA® technology) and, upon receipt of such payment (i) the related security agreements, security interests, liens, guaranties and payment obligations with respect to such note and the assets securing its repayment would terminate, (ii) Tolmar would execute a corresponding release and (iii) neither the Company nor Arius Two will have any further payment obligations to Tolmar under the note or BEMA® acquisition documents, except with respect to certain indemnification obligations of Arius Two. Arius Two paid the $1.05 million contemplated by the letter agreement on January 6, 2012, fully satisfying the outstanding balance of the note, and Tolmar subsequently executed its final release of the related security interests contemplated by the letter agreement. As a result, the Company now owns all rights to the BEMA® technology on a worldwide basis.

MidCap_Secured_Loan_Facility

MidCap Secured Loan Facility	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
MidCap Secured Loan Facility	'
	9	MidCap Secured Loan Facility:
	On July 5, 2013, the Company, Arius One and Arius Two (the “Borrowers”) entered into a $20 million secured loan facility (the “Loan Transaction” and such loan, the “Loan”) with MidCap as agent and lender pursuant to the terms and conditions of the Credit Agreement. The Company received net proceeds in the aggregate amount of $19.8 million and will use the Loan proceeds for general corporate purposes or other activities of the Borrower permitted under the Credit Agreement.
	In addition, pursuant to the Loan Transaction, the Company issued to MidCap a warrant (the “MidCap Warrant”) to purchase 357,356 unregistered shares of Common Stock, which warrant has an exercise price of $4.20 per share, the 20-day volume-weighted average share price of the Common Stock prior to the closing of the Loan. The MidCap Warrant is exercisable for a term of five (5) years and contains cashless exercise provisions and customary, anti-dilution protection provisions. The proceeds of the secured loan facility were allocated to the note payable and Midcap warrants (which qualified for equity accounting) based on their relative fair values, as follows:
	Note payable		$	19,013,648
	MidCap warrant			986,352
	Total proceeds		$	20,000,000
	The resulting debt discount is being amortized to interest expense over the 3 year life of the loan.
	The fair value of the warrants was determined based upon the Black Scholes valuation model using the following key assumptions:
	Market price of stock		$	4.41
	Term of warrant			5 years
	Volatility			81.05	%
	Risk free interest rate			2.9	%
	The Loan has a term of 36 months with interest only payments until February 1, 2014. The interest rate is 8.45% plus a LIBOR floor of 0.5% (total of 8.95% at December 31, 2013). Upon execution of the Credit Agreement, the Company paid to MidCap a closing fee of 0.5% of the aggregate Loan amount. Upon repayment in full of the Loan, the Company is obligated to make a final payment fee equal to 3.5% of the aggregate Loan amount. The 3.5% exit fee has been recorded as deferred loan costs, the current portion of which is included in prepaid expenses and other current assets and the long-term portion in other assets. Additionally, the liability associated with the exit fee has been recorded in other long-term liability in the accompanying 2013 consodilated balance sheet. The assets associated with this exit fee are accreted to interest expense through the maturity of the Midcap Loan. In addition, the Company may prepay all or any portion of the Loan at any time subject to a prepayment premium of: (i) 5% of the Loan amount prepaid in the first year of the Loan and (ii) 3% of the Loan amount prepaid in each year thereafter. In addition, if the Company receives the second of two anticipated database lock milestone payments (the “Database Lock Payments”) from Endo in connection with the Endo Agreement, the
	Company may prepay 50% of the principal amount of the Loan then outstanding and, concurrently and at the Company’s election, either: (i) pay to MidCap a cash prepayment fee of 2% of the principal amount of the Loan and all obligations thereunder outstanding as of the date of prepayment or (ii) issue to MidCap a warrant (in a form substantially similar to the MidCap Warrant) to purchase shares of Common Stock equal to 2.0% of the prepayment amount, with the number of shares being calculated using the Black-Scholes pricing model.
	The obligations of the Borrowers under the Credit Agreement are secured by a first priority lien in favor of MidCap on substantially all of the Borrowers’ existing and after-acquired assets, but excluding certain of the Borrowers’ intellectual property and general intangible assets of the Borrowers (but not any proceeds thereof). The obligations of the Company under the Loan Agreement are also secured by a first priority lien on the equity interests held by the Company in Arius One, Arius Two and BND. The Borrowers entered into customary pledge and intellectual property security agreements to evidence the security interest in favor of MidCap.
	Under the Credit Agreement, the Borrowers are subject to affirmative covenants which are customary for financings of this type, including, but not limited to, the obligations of the Borrowers to: (i) maintain good standing and governmental authorizations, (ii) provide certain information and notices to MidCap, (iii) deliver monthly and annual financial statements to MidCap, (iv) maintain insurance, (v) discharge all taxes, (vi) protect their intellectual property and (vii) generally protect the collateral granted to MidCap.
	The Borrowers are also subject to negative covenants customary for financings of this type, including, but not limited to, that without the prior consent of Midcap, they may not: (i) enter into a merger or consolidation or certain change of control events, (ii) incur liens on the collateral, (iii) incur additional indebtedness, (iii) dispose of any property, (iv) amend material agreements or organizational documents, (v) change their jurisdictions of organization or their organizational structures or types, (vi) declare or pay dividends (other than dividends payable solely in Common Stock), (vii) make certain investments or acquisitions, or (viii) enter into certain transactions with affiliates, in each case subject to certain exceptions provided for in the Credit Agreement, including exceptions that allow the Borrowers to acquire additional products and to enter into licenses and similar agreements provided certain conditions are met.
	The Credit Agreement provides that events of default include: (i) failure to make payment of principal or interest on the Loan when required, (ii) failure to perform obligations under the Credit Agreement and related documents, (iii) defaults in other indebtedness and breaches of material agreements of the Borrowers, (iv) if any Borrower shall generally not pay its debts as such debts become due and similar insolvency matters, (v) material adverse changes to the Borrowers (subject to a 10-day notice and cure period), (vi) if the Company ceases to be a publicly-listed and reporting company, (vii) failure to receive the Database Lock Payments by June 30, 2014, and (viii) certain other events, including certain adverse actions taken by the Food and Drug Administration or other governmental authorities. Upon an event of default, the Borrower’s obligations under the Credit Agreement may, or in the event of insolvency or bankruptcy will automatically, be accelerated. Upon the occurrence of any event of default, the Borrower’s obligations under the Credit Agreement will bear interest at a rate equal to the lesser of: (i) 4% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default and (ii) the maximum rate allowable under law. The balance of the secured loan facility due to MidCap as of December 31, 2013 is $20 million, and is recorded in the accompanying consolidated 2013 balance sheet, net of unamortized discount of $0.8 million.
	The following table represents future maturities of the MidCap obligation as of December 31, 2013:
	Years ending December 31,
	2014		$	7,333,333
	2015			8,000,000
	2016			4,666,667
	Total maturities			20,000,000
	Unamortized discount			(821,961	)
	Total Midcap obligation		$	19,178,039

Derivative_Financial_Instrumen

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	10	Derivative Financial Instruments:
	The Company generally does not use derivative instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. However, certain other financial instruments, such as warrants and embedded conversion features that are indexed to the Company’s Common Stock, are classified as liabilities when either: (a) the holder
	possesses rights to net-cash settlement or (b) physical or net-share settlement is not within the control of the Company. In such instances, net-cash settlement is assumed for financial accounting and reporting, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded at fair value estimated on the settlement date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, and then adjusted to fair value at the close of each reporting period.
	The following tabular presentation reflects the components of derivative financial instruments as of December 31, 2013, 2012 and 2011.
			2013			2012			2011
	Derivative gain (loss) in the accompanying statements of operations is related to the individual derivatives as follows:
	Free standing warrants assets, related party		$	(50,300	)	$	(338,500	)	$	(910,231	)
	Free standing warrants liabilities			171,528			(5,255,652	)		4,373,684
			$	121,228		$	(5,594,152	)	$	3,463,453
	The following table summarizes assets and liabilities measured at fair value on a recurring basis at December 31, 2013 and December 31, 2012, respectively:
			2013											2012
	Fair Value Measurements Using:		Level 1			Level 2			Level 3			Total		Level 1		Level 2		Level 3		Total
	Assets
	Derivative asset, warrant		$	—		$	—		$	—		$	—	$	—	$	50,300	$	—	$	50,300
	Liabilities
	Derivative liabilities		$	—		$	4,315,183		$	—		$	4,315,183	$	—	$	4,497,977	$	—	$	4,497,977
	The table below provides a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using significant observable inputs (Level 2). The table reflects net gains and losses for all financial assets and liabilities categorized as Level 2 as of December 31, 2012 and 2013.
	Fair Value Measurements Using Significant Observable Inputs (Level 2)
			Value of			Number of
			Warrants			Warrants
	Assets:
	Warrant asset as of January 1, 2012		$	388,540			2,000,000
	Decrease in fair value of warrants			(338,240	)		—
	Warrant asset as of December 31, 2012		$	50,300			2,000,000
	Decrease in fair value of warrants			(50,300	)		(2,000,000	)
	Warrant asset as of December 31, 2013		$	—			—
	Liabilities:
	Warrant liability as of January 1, 2012		$	279,302			3,246,301
	Decrease due to exercise of warrants			(1,037,237	)		(236,865	)
	Expiration of warrants			—			(1,000,000	)
	Increase in fair value of warrants			5,255,912			—
	Warrant liability as of December 31, 2012		$	4,497,977			2,009,436
	Decrease due to exercise of warrants			(11,266	)		(10,000	)
	Decrease in fair value of warrants			(171,528	)		—
	Warrant liability as of December 31, 2013		$	4,315,183			1,999,436

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	11	Income taxes:
	The Company had income tax expense in 2012 of $0.1 million. The Company did not record income tax expense in 2013 or 2011 as the Company had incurred net operating losses. The Company has recognized valuation allowances for all deferred tax assets for years ending 2013, 2012 and 2011. Reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:
			Year Ended December 31,
			2013			2012			2011
	Federal statutory income tax rate			34	%		34	%		34	%
	State taxes, net of federal benefit			3.45			3.45			3.45
	Permanent differences-derivative loss (gain)			0.11			110.51			7.02
	Permanent differences-other			(1.07	)		44.12			(2.76	)
	Research and development (“R&D”) credit			4.91			(129.12	)		2.92
	Other			0.64			(30.89	)		(6.63	)
	Valuation allowance			(42.04	)		(24.82	)		(38.00	)
				0	%		7.25	%		0	%
	The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following:
			December 31,
	Deferred tax assets (liabilities)		2013			2012
	Deferred revenue		$	1,576,186		$	4,010,493
	Basis difference in equipment			(890,387	)		(926,735	)
	Basis difference in intangibles			(501,709	)		(618,403	)
	Accrued liabilities and other			418,300			263,364
	R&D credit			10,366,432			8,720,314
	Stock options			2,199,794			1,557,756
	Net operating loss carry-forward (NOL)			40,494,523			16,575,544
				53,663,139			29,582,333
	Less: valuation allowance			(53,663,139	)		(29,582,333	)
			$	—		$	—
	In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As a result, the Company recorded a valuation allowance with respect to all of the Company’s deferred tax assets.
	The Company has a federal net operating loss (“NOLs”) of approximately $109 million as of December 31, 2013. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to May 16, 2006 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $1.5 million per year. The Company’s State NOLS are approximately $100 million as of December 31, 2013. These loss carryforwards expire principally beginning in 2020 through 2026 for federal and 2028 for state purposes.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	12	Stockholders’ equity:
	Common Stock
	On March 11, 2011, the Company closed a private placement financing, issuance and sale of Common Stock. The final amount of Common Stock issued in the offering was an aggregate of 4,807,693 shares of Common Stock.
	On December 3, 2012, the Company closed a registered direct offering, issuance and sale of Common Stock. The final amount of Common Stock issued in the offering was an aggregate of 6,791,887 shares of Common Stock.
	In November 2013, the Company filed a shelf registration statement which registered up to $75 million of the Company’s securities for potential future issuance, and such registration statement was declared effective on December 18, 2013. In January 2014, the Company pulled from the shelf registration 658,489 shares of common stock for approximate proceeds of $4 million.
	Preferred Stock
	The Company had authorized five million “blank check” shares of $.001 par value convertible preferred stock. On December 3, 2012, the Company closed a registered direct offering, issuance and sale of Series A Preferred. The final amount of Series Preferred issued in the offering was an aggregate of 2,709,300 shares of Series A Preferred. In the event of the Company’s liquidation, dissolution or winding up, holders of the Series A Preferred will receive a payment equal to $.001 per share of Series A Preferred before any proceeds are distributed to the holders of common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A Preferred, the holders of Series A Preferred will participate ratably in the distribution of any remaining assets with the common stock and any other class or series of our capital stock hereafter created that participates with the common stock in such distributions. At December 31, 2013, 2,709,300 shares of Series A Preferred were outstanding and 2,290,700 shares of “blank check” preferred stock remain authorized but undesignated.
	Restricted Stock Units:
	During the year ended December 31, 2012, a total of 57,500 RSUs were issued to independent directors pursuant to the Company’s 2011 Equity Incentive Plan and fully vested September 14, 2012. The expense related to the issuance of these RSUs was approximately $0.3 million in 2012 and was recorded in general and administrative expense in the consolidated statement of operations.
	During the year ended December 31, 2013, a total of 1,078,336 RSUs with a fair market value of approximately $4.5 million were granted to members of the Company’s senior management. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. These RSUs were issued under the Company’s 2011 Equity Incentive Plan, as amended, and vest in equal installments over three years. This grant was in lieu of the 2012 annual option grant typically given to senior management in order to bring the percentage ownership of senior management in line with the senior management of companies in the Company’s peer group.
	In addition, in June 2013, the Company issued 3,125 RSUs with a fair value of $0.01 million to a new board member, which vested immediately. The Company also issued in August 2013, a total of 118,853 RSUs to board members with a fair value of approximately $0.6 million, of which 63,853 RSUs vested immediately and the remaining 55,000 vest in August 2014.
	Performance Long Term Incentive Plan
	In December 2012, the Company approved the BDSI Performance Long Term Incentive Plan (“LTIP”). The LTIP is designed as an incentive for the Company’s senior management to generate revenue for the Company.
	The LTIP consists of Restricted Stock Units (as defined under the Company’s 2011 Equity Incentive Plan, and which is referred to as Performance RSUs) which are rights to acquire shares of the Company’s common stock. All Performance RSUs granted under the LTIP will be granted under the Company’s 2011 Equity Incentive Plan (as the same may be amended, supplemented or superseded from time to time) as “Performance Compensation Awards” under such plan. The participants in the LTIP are either named executive officers or senior officers of the Company.
	The term of the LTIP began with the Company’s fiscal year ended December 31, 2012 and lasts through the fiscal year ended December 31, 2019. The total number of Performance RSUs covered by the LTIP is 1,078,000, of which 978,000 were awarded in 2012 (with 100,000 Performance RSUs being reserved for future hires). The Performance RSUs under the LTIP did not vest upon granting, but instead are subject to potential vesting each year over the 8 year term of the LTIP depending on the achievement of revenue by our company, as reported in our Annual Report on Form 10-K. A total of 8,968 RSUs vested, subject to performance criteria, during the year ended December 31, 2013. The expense related to the issuance of these RSUs
	was approximately $0.03 million in 2012 and $0.9 million in 2013, and was recorded in general and administrative expense in the consolidated statement of operations. The fair value of RSUs is determined using actual market prices of the Common Stock and the number of shares expected to vest.
	Stock options:
	The Company has a 2011 Equity Incentive Plan, which was approved by stockholders in July 2011 and covers a total of 4,200,000 shares of Common Stock. An additional 3,192,596 shares of Common Stock underlying options previously granted under the Company’s Amended and Restated 2001 Incentive Plan remain outstanding and exercisable. The Company’s Amended and Restated 2001 Incentive Plan expired in July 2011 and no new securities may be issued thereunder. Options may be awarded during the ten-year term of the 2011 Equity Incentive Plan to Company employees, directors, consultants and other affiliates.
	Stock option activity for the years ended December 31, 2013, 2012 and 2011 is as follows:
			Number of			Weighted Average		Aggregate
			Shares			Exercise Price Per		Intrinsic
						Share		Value
	Outstanding at January 1, 2011			4,311,539		$	3.65
	Granted in 2011:
	Officers and Directors			209,619		$	3.44
	Others			238,918			3.41
	Exercised			(129,888	)		2.69
	Forfeitures			(76,937	)		3.09
	Outstanding at December 31, 2011			4,553,251		$	3.66	$	—
	Granted in 2012:
	Officers and Directors			281,174		$	2.36
	Others			485,540			2.8
	Exercised			(789,305	)		2.6
	Forfeitures			(250,741	)		3.26
	Outstanding at December 31, 2012			4,279,919		$	3.7	$	4,572,205
	Granted in 2013:
	Officers and Directors			55,659		$	5.39
	Others			223,135			4.47
	Exercised			(115,667	)		3.25
	Forfeitures			(250,119	)		2.89
	Outstanding at December 31, 2013			4,192,927		$	3.82	$	9,145,780
	Options outstanding at December 31, 2013 are as follows:
	Range of Exercise Prices		Number			Weighted Average		Weighted Average		Aggregate
			Outstanding			Remaining Contractual		Exercise Price		Intrinsic
						Life (Years)				Value
	$1.00 –   5.00			3,230,768			5.48	$	3.1
	$5.01 – 10.00			962,159			4.02	$	6.25
				4,192,927						$	9,145,780
	Options exercisable at December 31, 2013 are as follows:
	Range of Exercise Prices		Number			Weighted Average		Weighted Average		Aggregate
			Outstanding			Remaining Contractual		Exercise Price		Intrinsic
						Life (Years)				Value
	$1.00 –   5.00			2,671,959			4.78	$	3.03
	$5.01 – 10.00			906,500			3.66	$	6.3
				3,578,459						$	7,759,365
	The weighted average grant date fair value of options granted during the years ended December 31, 2013, 2012 and 2011 was $3.28, $1.97 and $3.43, respectively. There were no options granted during the years ended December 31, 2013, 2012 or 2011 whose exercise price was lower than the estimated market price of the stock at the grant date.
	Nonvested stock options as of December 31, 2013, and changes during the year then ended, are as follows:
	Nonvested Shares		Shares			Weighted Average		Intrinsic
						Grant Date Fair		Value
						Value
	Nonvested at January 1, 2013			854,640
	Granted			278,794
	Vested			(342,538	)
Forfeited			(176,428	)
Nonvested at December 31, 2013			614,468		$	2.59	$	1,386,415
As of December 31, 2013, there was approximately $4.6 million of unrecognized compensation cost related to unvested share-based compensation awards granted. These costs will be expensed over the next six years.
Warrants:
The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements.
Warrants outstanding and exercisable at December 31, 2013 are as follows:
Range of Exercise Prices		Number			Weighted Average		Weighted Average		Aggregate
		Outstanding			Remaining Contractual		Exercise Price		Intrinsic
					Life (Years)				Value
$0.00 – 5.00			2,356,792			1.44	$	3.92	$	4,640,492
The Company issued warrants to purchase 357,356 shares of Common Stock at a price of $4.20 in connection with a loan financing in July 2013 (note 9). The warrants had a fair value of approximately $1 million at the date of the grant.
Reclassification of derivative liability to equity:
During the year ended December 31, 2013, warrants by an investor were exercised to purchase 10,000 shares of Common Stock at $5.00 per share. Until the time of exercise, the aforementioned warrants were treated as a derivative liability. Upon exercise of the warrants, these amounts were reclassified to equity based on the fair value on the date of exercise.
During the year ended December 31, 2012, warrants by various investors were exercised to purchase 281,865 shares of Common Stock at prices ranging from $3.00 to $5.00 per share. Until the time of exercise, 236,865 of the aforementioned warrants were treated as a derivative liability. Upon exercise of the warrants, these amounts were reclassified to equity based on the fair value on the date of exercise.
During the year ended December 31, 2011, CDC IV, LLC (“CDC”) exercised warrants to purchase 601,120 shares of Common Stock for $2.91 per share. Until the time of exercise the warrants were treated as a derivative liability. Upon exercise of the warrants, these amounts were reclassified to equity based on the fair value on the date of exercise.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Retirement Plan	'
	13	Retirement plan:
	The Company sponsors a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code. The plan covers all employees who meet certain eligibility and participation requirements. Participants may contribute up to 90% of their eligible earnings, as limited by law. The Company makes a matching contribution equal to 100% on the first 5% of participant contributions to the plan. The Company made contributions of approximately $0.2 million in 2013 and $0.1 million in both 2012 and 2011.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	14	Commitments and contingencies:
	Operating leases:
	Since November 2007, the Company has leased space for their corporate offices. The lease expired in January 2013 and was amended for an additional 24 months. Lease expense for the corporate office was $0.1 million for years ended December 31, 2013 and 2012, respectively.
	The future minimum commitment on the remaining operating lease at December 31, 2013 is as follows:
	Years ending December 31,
	2014		$	118,665
	2015			29,806
			$	148,471
	Indemnifications:
	The Company’s directors and officers are indemnified against costs and expenses related to stockholder and other claims (i.e., only actions taken in their capacity as officers and directors) that are not covered by the Company’s directors and officers insurance policy. This indemnification is ongoing and does not include a limit on the maximum potential future payments, nor are there any recourse provisions or collateral that may offset the cost. No events have occurred as of December 31, 2013 which would trigger any liability under the agreement.
	Certain Rights of CDC
	The Company and CDC are parties to a Clinical Development and License Agreement, dated July 15, 2005 (as amended, the “CDLA”) pursuant to which CDC has previously provided funds to the Company for the development of the Company’s ONSOLIS® product. CDC is entitled to receive a mid-single digit royalty based on net sales of ONSOLIS®, including minimum royalties of $375,000 per quarter beginning in the second full year following commercial launch. The royalty term expires upon the latter of expiration of the patent or generic entry into a particular country.
	In September 2007, in connection with CDC’s consent to the North American Meda transaction, the Company, among other transactions with CDC, granted CDC a 1% royalty on sales of the next BEMA® product, including an active pharmaceutical ingredient other than fentanyl, to receive FDA approval (the “Next BEMA® Product”). In connection with the 1% royalty grant: (i) CDC shall have the option to exchange its royalty rights to the Next BEMA® Product in favor of royalty rights to a substitute BEMA® product, (ii) the Company shall have the right, no earlier than six (6) months prior to the initial commercial launch of the Next BEMA® Product, to propose in writing and negotiate the key terms pursuant to which it would repurchase the royalty from CDC, (iii) CDC’s right to the royalty shall immediately terminate at any time if annual net sales of the Next BEMA® Product equal less than $7.5 million in any calendar year following the third anniversary of initial launch of the product and CDC receives $18,750 in three (3) consecutive quarters as payment for CDC’s one percent (1%) royalty during such calendar year and (iv) CDC shall have certain information rights with respect to the Next BEMA® Product.
	The amount of royalties which the Company may be required to pay for the Next BEMA® Product (including estimates of the minimum royalties) is not presently determinable because product sales estimates cannot be reasonably determined and the regulatory approvals of the product for sale is not possible to predict. As such, the Company expects to record such royalties, if any, as cost of sales when and if such sales occur.
	On May 12, 2011, the Company entered into an Amendment to Clinical Development and License Agreement (the “CDLA Amendment”) by and among CDC V, LLC (“CDC”), NB Athyrium LLC (“Athyrium”). Athyrium holds certain rights, acquired from CDC, to receive royalties on sales of ONSOLIS®.
	Under the terms of the CDLA Amendment, among other matters, the parties agreed to increase the royalty rate to be received by CDC/Athyrium retroactively to the initial launch date of ONSOLIS® and, accordingly, the Company recorded $0.3 million as additional cost of product royalties for year ended December 31, 2011. In addition, certain terms of the CLDA were amended and restated to clarify that royalty payments by the Company under the CDLA will be calculated based on Meda’s sales of ONSOLIS®, whereas previous Company royalty payments to CDC were calculated based on Company sales of ONSOLIS® to Meda.
	The difference between these two calculations resulted in a $1.1 million overpayment by the Company which was recorded as a prepayment. As a result, the Company did not pay any of the quarterly royalty payments, including any 2011 payments due to CDC/Athyrium until the December 31, 2011 royalty calculation, which the Company paid during the first quarter of 2012.
	Litigation Related To ONSOLIS®
	On November 2, 2010, MonoSol Rx, LLC (“MonoSol”) filed an action against the Company and its commercial partners for ONSOLIS® in the Federal District Court of New Jersey (“DNJ”) for alleged patent infringement and false marking. The Company was formally served in this matter on January 19, 2011. MonoSol claims that the Company’s manufacturing process for ONSOLIS®, which has never been disclosed publicly and which the Company and its partners maintain as a trade secret, infringes its patent (United States Patent No. 7,824,588) (the “ ‘588 Patent”). Of note, the BEMA® technology itself is not at issue in the case, nor is BEMA® Buprenorphine or BUNAVAIL™, but rather only the manner in which ONSOLIS®, which incorporates the BEMA® technology, is manufactured. Pursuant to its complaint, MonoSol is seeking an unspecified amount of damages, attorney’s fees and an injunction preventing future infringement of MonoSol’s patents.
	The Company strongly refutes as without merit MonoSol’s assertion of patent infringement, which relates to its confidential, proprietary manufacturing process for ONSOLIS®. On February 23, 2011, the Company filed its initial answer in this case. In the Company’s answer, the Company stated its position that their products, methods and/or components do not infringe MonoSol’s ‘588 Patent because they do not meet the limitations of any valid claim of such patent. Moreover, in the Company’s answer, the Company stated its position that MonoSol’s ‘588 Patent is actually invalid and unenforceable for failure to comply with one or more of the requirements of applicable U.S. patent law.
	On September 12, 2011, the Company filed a request for inter partes reexamination in the United States Patent and Trademark Office (“USPTO”) of MonoSol’s ‘588 Patent demonstrating that all claims of such patent were anticipated by or obvious in the light of prior art references, including several prior art references not previously considered by the USPTO, and thus invalid. On September 16, 2011, the Company filed in court a motion for stay pending the outcome of the reexamination proceedings, which subsequently was granted due to the results of the USPTO proceedings as described below.
	On November 28, 2011, the Company announced that it was informed by the USPTO that it had rejected all 191 claims of MonoSol’s ‘588 Patent. On January 20, 2012, the Company filed requests for reexamination before the USPTO of MonoSol’s US patent No 7,357,891 (the “‘891 Patent”), and No 7,425,292 (the “‘292 Patent”), the two additional patents asserted by MonoSol, demonstrating that all claims of those two patents were anticipated by or obvious in the light of prior art references, including prior art references not previously considered by the USPTO, and thus invalid.
	In February and March 2012, respectively, the USPTO granted the requests for reexamination we filed with respect to MonoSol’s ‘292 and ‘891 Patents. In its initial office action in each, the USPTO rejected every claim in each patent. Based on the action of the USPTO on these three patent reexaminations, the court in the Company’s case with MonoSol conducted a status conference on March 7, 2012, at which it granted the Company’s motion to stay the case pending final outcome of the reexamination proceedings in the USPTO.
	As expected, in the ‘891 Patent and ‘292 Patent Ex Parte Reexamination proceedings, MonoSol amended the claims several times and made multiple declarations and arguments in an attempt to overcome the rejections made by the USPTO. These amendments, declarations and other statements regarding the claim language significantly narrowed the scope of their claims in these two patents. In the case of the ‘891 Patent, not one of the original claims survived reexamination and five separate amendments were filed confirming the Company’s position that the patent was invalid. Additionally, the Company believes that arguments and admissions made by MonoSol prevent it from seeking a broader construction during any subsequent litigation by employing arguments or taking positions that contradict those made during prosecution.
	A Reexamination Certificate for MonoSol’s ‘891 Patent in its amended form was issued August 21, 2012 (Reexamined Patent No. 7,357,891C1 or the ‘891C1 Patent). A Reexamination Certificate for MonoSol’s ‘292 Patent in its amended form was issued on July 3, 2012 (Reexamined Patent No. 7,425,292C1 or the ‘292C1 Patent). These actions by the USPTO confirm the invalidity of the original patents and through the narrowing of the claims in the reissued patents strengthens the Company’s original assertion that its products and technologies do not infringe on MonoSol’s original patents.
	Inter partes reviews, a new USPTO process to review the patentability of one or more claims of patents, was enacted in September, 2012. As such, on June 12, 2013, despite the Company’s previously noted success in the prior ex parte reexaminations for the ’292 and ’891 Patents, the Company availed ourselves of this new process and filed requests for inter partes reviews on the narrowed yet reexamined patents, the ‘292C1 and ‘891C1 Patents, to challenge their validity and continue to strengthen its position. This inter partes review process allows the Company to actively participate in the reviews and address any of MonoSol’s arguments and representations made during the review process, which heightens the Company’s ability to invalidate these patents. On November 13, 2013, the USPTO decided not to institute the two inter partes reviews for the ‘891C1 and ‘292C1 Patents. The USPTO’s decision was purely on statutory grounds and based on a technicality (in that the IPRs were not filed within what the UPSTO determined to be the statutory period) rather than substantive grounds. Thus, even though the inter partes reviews were not instituted, the USPTO decision preserves the Company’s right to raise the same arguments at a later time (e.g., during litigation). Regardless, the Company’s assertion that its products and technologies do not infringe the original ‘292 and ‘891 Patents and, now, the reexamined ‘891C1 and ‘292C1 Patents remains the same.
	Importantly, in the case of MonoSol’s ‘588 Patent, the USPTO on July 20, 2012 issued a second Office Action closing prosecution and rejecting for a second time all claims as anticipated or obvious. It also rejected the amended claims proposed by MonoSol as unclear and lacking support. Then, on January 23, 2013, the USPTO issued a Right of Appeal Notice, rejecting all claims of the ‘588 Patent and closing reexamination proceedings. This action confirms that all claims of this patent are also invalid, but unlike ‘292 and ‘891, the USPTO has not found that any amended or narrower claims should be granted. On February 22, 2013, MonoSol filed both a Notice of Appeal to the Board of Patent Appeals and Interferences and a Request for Continuing Examination of the ‘588 Patent. On March 12, 2013, the Company filed a petition requesting the USPTO to deny MonoSol’s February 22, 2013 Request to Continue Examination and to allow the proceedings to go to an appeal. Subsequently, on July 3, 2013, the USPTO denied MonoSol’s February 22, 2013 Request to Continue Examination. After reviewing MonoSol’s Appeal Brief (filed June 24, 2013) and the Company’s Respondent’s Brief (filed July 24, 2013), the USPTO formally initiated the appeals process with the Examiner’s Answer on August 8, 2013, which affirmed the rejection of all the claims in the ‘588 Patent. An oral hearing for the appeal, in which both parties will have an opportunity to make arguments before the Patent Trial & Appeal Board (“PTAB”) has been scheduled for March 26, 2014.
	Based on the Company’s original assertion that our proprietary manufacturing process for ONSOLIS® does not infringe on patents held by MonoSol, and the denial and subsequent narrowing of the claims on the two reissued patents MonoSol has asserted against the Company while the third has had all claims rejected by the USPTO, the Company remains very confident in its original stated position regarding this matter. Thus far, the Company has proven that the “original” ‘292 and ‘891 patents in light of their reissuance with fewer and narrower claims were indeed invalid and the third and final patent, ‘588, has had all claims rejected and appears to have had a similar fate. Importantly, the Company will continue to defend this case vigorously, and anticipates that MonoSol’s claims against the Company will ultimately be rejected.
	Litigation Related To BUNAVAIL™
	On October 29, 2013, Reckitt Benckiser, Inc., RB Pharmaceuticals Limited, and MonoSol (collectively, the “RB Plaintiffs”) filed an action against the Company relating to its BUNAVAIL™ product in the United States District Court for the Eastern District of North Carolina for alleged patent infringement. BUNAVAIL™ is a proposed treatment for opioid dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL™, which has never been disclosed publicly, infringes its patent (United States Patent No. 8,475,832) (the “‘832 Patent”). The Company believes this is another anticompetitive attempt by the RB Plaintiffs to distract the Company’s efforts from commercializing BUNAVAIL™.
	The Company believes that this action is in response to a 2013 decision wherein the FDA recently ruled in favor of the Company’s position in two Citizen Petitions filed by the RB Plaintiffs that sought to prevent the FDA from accepting and filing the Company’s NDA for BUNAVAIL™. The two Citizen Petitions, filed on December 2, 2011 and August 13, 2013, respectively, included requests that the FDA refuse to accept for filing any NDAs submitted using the 505 (b)(2) regulatory pathway for buprenorphine/naloxone products consisting of a polymer film for application to the buccal mucosal membranes (such as BUNAVAIL™), unless such application references the NDA for Suboxone® (buprenorphine/naloxone) sublingual film (and not the Suboxone® sublingual tablet NDA). Suboxone® is an approved product for opioid dependence. The requirement to reference the Suboxone® film formulation, which is under patent exclusivity with Orange Book-listed patents, including the ‘832 Patent, was aimed at delaying the eventual approval of BUNAVAIL™. FDA did not agree with these arguments and in its decision on September 18, 2013, it denied the requests and subsequently, accepted and filed the BUNAVAIL™ NDA.
	The Company believes that the RB Plaintiff’s claim of patent infringement has no more validity than the recently rejected Citizen Petitions, but is being used as another anticompetitive attempt to distract the Company in our efforts toward commercializing BUNAVAIL™. We look forward to the FDA’s review of the BUNAVAIL™ NDA as it moves toward the June 7, 2014 Prescription Drug User Fee Act (“PDUFA”) date when we expect a response from FDA on our NDA for BUNAVAIL™. In the meantime, the Company strongly refutes as without merit the RB Plaintiffs’ assertion of patent infringement and will vigorously defend the lawsuit.
	On December 13, 2013, the Company filed a motion to dismiss RB Plaintiff’s suit based on insufficient pleadings and lack of standing. In response, RB Plaintiffs filed its opposition to the Company’s motion to dismiss on January 22, 2014. The Company filed its reply to RB’s opposition to the Company’s motion to dismiss on February 10, 2014.
	On January 15, 2014, the Company filed a request for inter partes review in the USPTO of the ‘832 Patent demonstrating that certain claims of such patent were anticipated by or obvious in the light of prior art references, including prior art references not previously considered by the USPTO, and thus, invalid. On January 31, 2014, the Company filed in Court a motion for stay pending the outcome of the inter partes review proceedings.

Selected_Quarterly_Results_Una

Selected Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Results (Unaudited)	'
	SELECTED QUARTERLY RESULTS (UNAUDITED)
	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data):
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Revenue	$	1,622		$	2,764		$	2,997		$	3,973
	Gross profit		1,247			2,074			2,354			3,599
	Loss from operations		(13,712	)		(13,808	)		(17,083	)		(11,799	)
	Net loss		(12,723	)		(13,415	)		(18,486	)		(12,770	)
	Basic loss per share		(0.34	)		(0.35	)		(0.49	)		(0.33	)
	Diluted loss per share		(0.34	)		(0.35	)		(0.49	)		(0.33	)
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Revenue	$	16,518		$	16,298		$	1,875		$	19,851
	Gross profit		16,143			15,923			1,500			19,066
	Income (loss) from operations		8,565			7,148			(14,059	)		5,408
	Net income (loss)		6,751			3,783			(17,477	)		8,596
	Basic income (loss) per share		0.23			0.13			(0.58	)		0.26
	Diluted income (loss) per share		0.23			0.12			(0.58	)		0.19

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts and Reserves	'
	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
	Years ended December 31, 2013, 2012 and 2011
		Balance at		Charged		Charged to			Balance at
		beginning of		to income		other			the end of
		the period				accounts			the period
		(In millions)
	Description
	Valuation allowance for deferred tax assets
	Year ended December 31, 2013:	$	29.58	$	—	$	24.08		$	53.66
	Year ended December 31, 2012:	$	30.13	$	—	$	(0.55	)	$	29.58
	Year ended December 31, 2011:	$	21.27	$	—	$	8.86		$	30.13

Nature_of_Business_and_Summary1

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization	'
	Organization:
	BioDelivery Sciences International, Inc. (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company and its subsidiaries, Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”) are collectively referred herein to as the “Company.”
	The Company is a specialty pharmaceutical company that is leveraging its novel, proprietary and patented BioErodible MucoAdhesive (“BEMA®”) drug delivery technology to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics, primarily in the areas of pain management and oncology supportive care. The Company’s development strategy focuses on utilization of the U.S. Food and Drug Administration’s (“FDA”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved therapeutics.
	As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock”.
Principles of Consolidation	'
	Principles of consolidation:
	The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. BND is currently and has for several years been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated.
Cash and Cash Equivalents	'
	Cash and cash equivalents:
	Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company’s cash equivalents include Ultra Short Term Government Funds. Because of the short-term maturities of the Company’s cash and cash equivalents, the Company does not believe that an increase in market rates would have a significant impact on the realized value of its investments. The Company places cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $250,000 for substantially all depository accounts. The Company may from time to time have amounts on deposit in excess of the insured limits. As of December 31, 2013, the Company had approximately $22.8 million, which exceed these insured limits.
Revenue Recognition	'
	Revenue recognition:
	The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through up-front payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 5, 6, 7 and 8.
	Meda License, Development and Supply Agreement:
	General
	The Company entered into license, development and supply agreements (collectively, the “Meda Agreements”) with Meda AB, a Swedish company (“Meda”), in September 2007 (covering the United States, Canada and Mexico) and August 2006 (covering certain countries in Europe) to develop and commercialize the Company’s sole FDA-approved and marketed product, ONSOLIS® (fentanyl buccal soluble film), a treatment with an initial indication for “breakthrough” cancer pain. ONSOLIS® is a product consisting of the narcotic fentanyl formulated with the Company’s patented BEMA® technology. The Company’s deliverables under the Meda Agreements, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 5.
	License and product development research and development services revenue
	Based on the Company’s assessment of each arrangement, all deliverables under the Meda Agreements have been accounted for as one combined unit of accounting and, as such, all cash payments from Meda (upfront payments and product development research and development services revenue) related to these deliverables were recorded as deferred revenue. Upon delivery of the license rights to Meda in October 2009, the Company recognized revenue associated with the license and the research and development services rendered related to development of the ONSOLIS® product through the date of FDA and other governmental approval. A portion of the upfront payments have been attributed to the Company’s continuing obligation to participate in joint committees with Meda and to provide certain other specified services and this revenue will be recognized as services are provided through expiration of the license agreements.
	Endo License and Development Agreement:
	General
	The Company entered into a worldwide license and development agreement (the “Endo Agreement”) with Endo Pharmaceuticals, Inc. (“Endo”) in January 2012 to develop and commercialize the Company’s product candidate BEMA® Buprenorphine. BEMA® Buprenorphine is a partial mu-opioid agonist and a potential treatment for moderate to severe chronic pain. The Company’s deliverables under the Endo Agreement, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 6.
	License and product development research and development services revenue
	Upon delivery of the license rights for BEMA® Buprenorphine to Endo in January 2012, the Company recognized revenue of $15.6 million of the $30 million non-refundable up-front license fee, with the balance of $14.4 million recorded as deferred revenue to be recognized as the related research and development services are rendered. Of the amount deferred, the Company recognized $5.2 million as revenue in 2012 and $6.3 million as revenue in 2013. In addition, in May 2012 the Company received and recognized $15 million in revenue associated with an intellectual property milestone under the Endo Agreement.
	Arcion License Agreement:
	General
	The Company entered into a definitive exclusive license agreement (the “Arcion Agreement”) with Arcion in March 2013 pursuant to which Arcion agreed to grant to the Company an exclusive commercial world-wide license, with rights of sublicense, under certain patent and other intellectual property rights related to in-process research and development to develop, manufacture, market, and sell gel products containing clonidine (or a derivative thereof), alone or in combination with other active ingredients, for topical administration for the treatment of painful diabetic neuropathy and other indications (the “Arcion Products”). The Arcion Agreement, including the Company’s related rights and obligations, contractual cash flows and performance periods, are more fully described in note 7.
	Upon receipt of the license rights for clonidine from Arcion in March 2013, the Company made a payment to Arcion of $2.1 million in unregistered Common Stock in exchange for in-process research and development that has been recorded as research and development expense for the year ended December 31, 2013. The Company is also responsible for using commercially reasonable efforts to develop and commercialize Arcion Products, including the use of such efforts to conduct certain clinical trials within certain time frames.
Contract Revenue	'
	Contract Revenue
	The Company earned contract revenue as a result of Meda up-front and milestone payments related to ONSOLIS®. Upon FDA approval of ONSOLIS® in July 2009, and the subsequent commercial launch of ONSOLIS® in October 2009, the Company recognized this contract revenue. The Company also recognized contract revenue as a result of the approval and subsequent launch of BREAKYL™ in the E.U. in 2012.
	The Company also earned contract revenue related to two similar license, development and supply agreements covering different territories: (i) Kunwha Pharmaceutical Co., Ltd., a Republic of Korea corporation (“Kunwha”), to develop, manufacture, sell and distribute BEMA® Fentanyl in the Republic of Korea, and (ii) TTY Biopharm Co., Ltd., a Taiwanese company (“TTY”), to develop, manufacture, sell and distribute the Company’s BEMA® Fentanyl product in Taiwan. Upfront payments from Kunwha and TTY are recorded as contract revenue upon receipt. The Company earned contract revenues in 2011 and 2013 related to milestones from TTY upon government approvals.
Research and Development Reimbursements	'
	Research and Development Reimbursements
	The Company is reimbursed by Endo for certain contractor costs when these costs go beyond set thresholds as outlined in the License and Development Agreement dated January 5, 2012 between the Company and Endo. Endo reimburses the Company for this spending at cost and the Company receives no mark-up or profit. The gross amount of these reimbursed research and development costs are reported as revenue in the accompanying consolidated statements of operations. The Company acts as a principal, has discretion to choose suppliers, bears credit risk and may perform part of the services required in the transactions. Therefore, these reimbursements are treated as revenue to the Company. The actual expenses creating the reimbursements are reflected as research and development expense.
Cost of Product Royalties	'
	Cost of Product Royalties
	The cost of product royalties includes the direct costs attributable to the production of ONSOLIS® and BREAKYL™. It includes all costs related to creating the product at the Company’s contract manufacturing locations in the U.S. and Germany. The Company’s contract manufacturers bill the Company for the final product, which includes materials, direct labor costs, and certain overhead costs as outlined in applicable supply agreements. Cost of product royalties also includes royalty expenses that the Company owes to third parties.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.
Certain Risks, Concentrations and Uncertainties	'
	Certain Risks, Concentrations and Uncertainties
	The Company’s product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates that have not yet been so approved, there is a risk that they will not receive necessary approval. If approval is denied or delayed, it may have a material adverse impact on the Company. In addition, the Company’s products compete in rapidly changing, highly competitive markets which are characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements and developing industry standards. Any failure by the Company to anticipate or to respond adequately to scientific developments, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company’s business, operating results and future cash flows.
	Accounts receivable from one customer (Endo) accounted for 99.6% and from another customer (Meda) accounted for 83% of the Company’s trade accounts receivable at December 31, 2013 and December 31, 2012, respectively. Deferred revenue balances relate to the Meda and Endo Agreements at December 31, 2013 and 2012. The Company depends significantly upon the collaboration with Meda and Endo, and its activities may be impacted if these relationships are disrupted.
	Key components used in the manufacture of ONSOLIS® are currently provided by a sole or a limited number of suppliers. This could result in the Company’s inability to timely obtain an adequate supply of required components and reduce control over pricing, quality and timely delivery. Also, if the supply of any components is interrupted, components from alternative suppliers may not be available in sufficient volumes within required time frames, if at all, to meet the Company’s obligations under the Meda supply agreements. This could delay timely commercialization efforts by Meda, causing the Company to lose royalty revenue and potentially harming its reputation.
Deferred Revenue	'
	Deferred revenue
	Consistent with the Company’s revenue recognition policy, deferred revenue represents cash received in advance for licensing fees, consulting, research and development services and related supply agreements. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date.
Equipment	'
	Equipment
	Office and manufacturing equipment are carried at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to ten years.
	Due to the postponement of the U.S. re-launch of ONSOLIS® (note 5), related manufacturing equipment, net, totaling $2.8 million has been deemed idle, and has been reclassified to idle equipment, net in the accompanying consolidated balance sheet as of December 31, 2013. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has not recorded any impairment of this equipment during the year ended December 31, 2013 because; (i) the Company believes that the equipment will be utilized again once ONSOLIS® is re-launched and (ii) the equipment will be used in the manufacturing of BUNAVAIL™ if approved by the FDA.
Intangibles and Goodwill	'
	Intangibles and Goodwill
	The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its long-lived assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.
	There was no impairment charges recognized on finite lived intangibles in 2013, 2012 or 2011.
	Intangible assets with finite useful lives are amortized over the estimated useful lives as follows:
		Estimated
		Useful Lives
	Licenses	15 years
	U.S. Product rights	10-12 years
	EU Product rights	11 years
	The Company incurred amortization expense on other intangible assets of approximately $1.0 million, $1.0 million and $0.9 million for the years ended December 31, 2013, 2012 and 2011, respectively. Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows:
	Years ending December 31,
	2014	$	970,356
	2015		970,356
	2016		970,356
	2017		970,356
	2018		970,356
	Thereafter		344,718
		$	5,196,498
	Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. In the course of the evaluation of the potential impairment of Goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether impairment has occurred, a quantitative evaluation is performed. The quantitative impairment analysis involves a two-step process. Step one involves the comparison of the fair value of the reporting unit to which goodwill relates (the Company’s enterprise value) to the carrying value of the reporting unit. If the fair value exceeds the carrying value, there is no impairment. If the carrying value exceeds the fair value of the reporting unit, the Company determines the implied fair value of goodwill and records an impairment charge for any excess of the carrying value of goodwill over its implied fair value. There were no goodwill impairment charges in 2013, 2012 or 2011.
Use of Estimates in Financial Statements	'
	Use of estimates in financial statements:
	The preparation of the accompanying consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.
Net (loss) Income per Common Share	'
	Net (loss) income per common share:
	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2013, 2012 and 2011.
		December 31,
		2013			2012		2011
	Basic:
	Net (loss) income attributable to common stockholders	$	(57,393,613	)	$	1,652,181	$	(23,325,116	)
	Weighted average common shares outstanding		37,941,044			30,546,581		28,322,477
	Basic earnings per common share	$	(1.51	)	$	0.05	$	(0.82	)
	Diluted:
	Effect of dilutive securities:
	Net (loss) income attributable to common stockholders		(57,393,613	)		1,652,181		(23,325,116	)
	Adjustments to income for dilutive options and warrants		—			—		—
			(57,393,613	)		1,652,181		(23,325,116	)
	Weighted average common shares outstanding		37,941,044			30,546,581		28,322,477
	Effect of dilutive options and warrants		—			142,654		—
	Diluted weighted average common shares outstanding		37,941,044			30,689,235		28,322,477
	Diluted earnings per common share	$	(1.51	)	$	0.05	$	(0.82	)
	Basic earnings per common share is calculated using the weighted average shares of Common Stock outstanding during the period. Common equivalent shares from stock options and warrants using the treasury stock method, are also included in the diluted per share calculations unless the effect of inclusion would be antidilutive. During the years ended December 31, 2013, 2012 and 2011, outstanding stock options and warrants of 6,549,719, 5,509,075 and 7,847,052, respectively, were not included in the computation of diluted earnings per common share, because to do so would have had an antidilutive effect because the outstanding exercise prices were greater than the average market price of the common shares during the relevant periods.
Stock-based Compensation	'
	Stock-based compensation:
	The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common
	Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield.
	In applying the Black Scholes options-pricing model, assumptions are as follows:
		2013		2012	2011
	Expected price volatility	77.59%-81.65%		81.96%-83.69%	69.05%-77.75%
	Risk-free interest rate	0.70%-1.60%		0.62%-1.02%	0.90%-1.99%
	Weighted average expected life in years	5-6 years		5-6 years	5-6 years
	Dividend yield	—		—	—
Fair Value of Financial Assets and Liabilities	'
	Fair Value of Financial Assets and Liabilities
	The Company measures the fair value of financial assets and liabilities in accordance with generally accepted accounting principles of the United States (“GAAP”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Derivative Instruments	'
	Derivative instruments:
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain other financial instruments and contracts, such as debt financing arrangements and freestanding warrants with features that are either not afforded equity classification, embody risks not clearly and closely related to host contracts, or may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value, in the Company’s consolidated financial statements.
	The Company estimates fair values of derivative financial instruments using the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fairly value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the Company’s trading market price which has high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company’s income will reflect the volatility in these estimate and assumption changes.
Recent Accounting Pronouncements	'
	Recent accounting pronouncements:
	In July 2012, the FASB issued ASU 2012-02 – Testing Indefinite-Lived Intangible Assets for Impairment (“ASU 2012-02”) in order to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance. The new guidance allows an entity the option to make a qualitative assessment about the likelihood that an indefinite-lived intangible asset is impaired to determine whether it should perform a quantitative impairment test. ASU 2012-02 was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012 and early adoption was permitted.
	The Company adopted this standard on January 1, 2013. The adoption of this standard had no material impact on the Company’s consolidated financial statements.

Nature_of_Business_and_Summary2

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives	'
	Intangible assets with finite useful lives are amortized over the estimated useful lives as follows:
		Estimated
		Useful Lives
	Licenses	15 years
	U.S. Product rights	10-12 years
	EU Product rights	11 years
Estimated Aggregate Future Amortization Expenses for Other Intangible Assets	'
	Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows:
	Years ending December 31,
	2014	$	970,356
	2015		970,356
	2016		970,356
	2017		970,356
	2018		970,356
	Thereafter		344,718
		$	5,196,498
Reconciliation of the Numerators and Denominators of the Basic and Diluted Earnings Per Common Share Computations	'
	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2013, 2012 and 2011.
		December 31,
		2013			2012		2011
	Basic:
	Net (loss) income attributable to common stockholders	$	(57,393,613	)	$	1,652,181	$	(23,325,116	)
	Weighted average common shares outstanding		37,941,044			30,546,581		28,322,477
	Basic earnings per common share	$	(1.51	)	$	0.05	$	(0.82	)
	Diluted:
	Effect of dilutive securities:
	Net (loss) income attributable to common stockholders		(57,393,613	)		1,652,181		(23,325,116	)
	Adjustments to income for dilutive options and warrants		—			—		—
			(57,393,613	)		1,652,181		(23,325,116	)
	Weighted average common shares outstanding		37,941,044			30,546,581		28,322,477
	Effect of dilutive options and warrants		—			142,654		—
	Diluted weighted average common shares outstanding		37,941,044			30,689,235		28,322,477
	Diluted earnings per common share	$	(1.51	)	$	0.05	$	(0.82	)
Black Scholes Options-Pricing Model, Assumptions	'
	In applying the Black Scholes options-pricing model, assumptions are as follows:
		2013		2012	2011
	Expected price volatility	77.59%-81.65%		81.96%-83.69%	69.05%-77.75%
	Risk-free interest rate	0.70%-1.60%		0.62%-1.02%	0.90%-1.99%
	Weighted average expected life in years	5-6 years		5-6 years	5-6 years
	Dividend yield	—		—	—

Equipment_Tables

Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Equipment	'
	Equipment consists of the following:
		December 31,
		2013			2012
	Office and laboratory equipment	$	4,761,418		$	4,366,797
	Less accumulated depreciation		(1,738,532	)		(1,531,090	)
		$	3,022,886		$	2,835,707
	Less idle equipment		(2,844,718	)		—
		$	178,168		$	2,835,707

MidCap_Secured_Loan_Facility_T

MidCap Secured Loan Facility (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule Showing Allocation of Secured Loan Facility to Notes Payable and Midcap Warrants	'
	The proceeds of the secured loan facility were allocated to the note payable and Midcap warrants (which qualified for equity accounting) based on their relative fair values, as follows:
	Note payable	$	19,013,648
	MidCap warrant		986,352
	Total proceeds	$	20,000,000
Schedule of Fair Value of Warrants Based Upon the Black Scholes Valuation Model Assumptions	'
	The fair value of the warrants was determined based upon the Black Scholes valuation model using the following key assumptions:
	Market price of stock	$	4.41
	Term of warrant		5 years
	Volatility		81.05	%
	Risk free interest rate		2.9	%
Future Maturities of MidCap Obligation	'
	The following table represents future maturities of the MidCap obligation as of December 31, 2013:
	Years ending December 31,
	2014	$	7,333,333
	2015		8,000,000
	2016		4,666,667
	Total maturities		20,000,000
	Unamortized discount		(821,961	)
	Total Midcap obligation	$	19,178,039

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Components of (Expense) Income of Derivative Financial Instruments	'
	The following tabular presentation reflects the components of derivative financial instruments as of December 31, 2013, 2012 and 2011.
		2013			2012			2011
	Derivative gain (loss) in the accompanying statements of operations is related to the individual derivatives as follows:
	Free standing warrants assets, related party	$	(50,300	)	$	(338,500	)	$	(910,231	)
	Free standing warrants liabilities		171,528			(5,255,652	)		4,373,684
		$	121,228		$	(5,594,152	)	$	3,463,453
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following table summarizes assets and liabilities measured at fair value on a recurring basis at December 31, 2013 and December 31, 2012, respectively:
		2013											2012
	Fair Value Measurements Using:	Level 1			Level 2			Level 3			Total		Level 1		Level 2		Level 3		Total
	Assets
	Derivative asset, warrant	$	—		$	—		$	—		$	—	$	—	$	50,300	$	—	$	50,300
	Liabilities
	Derivative liabilities	$	—		$	4,315,183		$	—		$	4,315,183	$	—	$	4,497,977	$	—	$	4,497,977
Reconciliation of Beginning and Ending Balances of Assets and Liabilities Measured at Fair Value Using Significant Observable Inputs	'
	Fair Value Measurements Using Significant Observable Inputs (Level 2)
		Value of			Number of
		Warrants			Warrants
	Assets:
	Warrant asset as of January 1, 2012	$	388,540			2,000,000
	Decrease in fair value of warrants		(338,240	)		—
	Warrant asset as of December 31, 2012	$	50,300			2,000,000
	Decrease in fair value of warrants		(50,300	)		(2,000,000	)
	Warrant asset as of December 31, 2013	$	—			—
	Liabilities:
	Warrant liability as of January 1, 2012	$	279,302			3,246,301
	Decrease due to exercise of warrants		(1,037,237	)		(236,865	)
	Expiration of warrants		—			(1,000,000	)
	Increase in fair value of warrants		5,255,912			—
	Warrant liability as of December 31, 2012	$	4,497,977			2,009,436
	Decrease due to exercise of warrants		(11,266	)		(10,000	)
	Decrease in fair value of warrants		(171,528	)		—
	Warrant liability as of December 31, 2013	$	4,315,183			1,999,436

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Reconciliation of Federal Statutory Income Tax Rate	'
	Reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:
		Year Ended
		December 31,
		2013			2012			2011
	Federal statutory income tax rate		34	%		34	%		34	%
	State taxes, net of federal benefit		3.45			3.45			3.45
	Permanent differences-derivative loss (gain)		0.11			110.51			7.02
	Permanent differences-other		(1.07	)		44.12			(2.76	)
	Research and development (“R&D”) credit		4.91			(129.12	)		2.92
	Other		0.64			(30.89	)		(6.63	)
	Valuation allowance		(42.04	)		(24.82	)		(38.00	)
			0	%		7.25	%		0	%
Significant Components of Deferred Tax Assets and Liabilities	'
	The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following:
		December 31,
	Deferred tax assets (liabilities)	2013			2012
	Deferred revenue	$	1,576,186		$	4,010,493
	Basis difference in equipment		(890,387	)		(926,735	)
	Basis difference in intangibles		(501,709	)		(618,403	)
	Accrued liabilities and other		418,300			263,364
	R&D credit		10,366,432			8,720,314
	Stock options		2,199,794			1,557,756
	Net operating loss carry-forward (NOL)		40,494,523			16,575,544
			53,663,139			29,582,333
	Less: valuation allowance		(53,663,139	)		(29,582,333	)
		$	—		$	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Summary of Stock Option Activity	'
	Stock option activity for the years ended December 31, 2013, 2012 and 2011 is as follows:
		Number of			Weighted Average		Aggregate
		Shares			Exercise Price Per		Intrinsic
					Share		Value
	Outstanding at January 1, 2011		4,311,539		$	3.65
	Granted in 2011:
	Officers and Directors		209,619		$	3.44
	Others		238,918			3.41
	Exercised		(129,888	)		2.69
	Forfeitures		(76,937	)		3.09
	Outstanding at December 31, 2011		4,553,251		$	3.66	$	—
	Granted in 2012:
	Officers and Directors		281,174		$	2.36
	Others		485,540			2.8
	Exercised		(789,305	)		2.6
	Forfeitures		(250,741	)		3.26
	Outstanding at December 31, 2012		4,279,919		$	3.7	$	4,572,205
	Granted in 2013:
	Officers and Directors		55,659		$	5.39
	Others		223,135			4.47
	Exercised		(115,667	)		3.25
	Forfeitures		(250,119	)		2.89
	Outstanding at December 31, 2013		4,192,927		$	3.82	$	9,145,780
Summary of Stock Options Outstanding	'
	Options outstanding at December 31, 2013 are as follows:
	Range of Exercise Prices	Number			Weighted Average		Weighted Average		Aggregate
		Outstanding			Remaining Contractual		Exercise Price		Intrinsic
					Life (Years)				Value
	$1.00 –   5.00		3,230,768			5.48	$	3.1
	$5.01 – 10.00		962,159			4.02	$	6.25
			4,192,927						$	9,145,780
Summary of Stock Options Exercisable	'
	Options exercisable at December 31, 2013 are as follows:
	Range of Exercise Prices	Number			Weighted Average		Weighted Average		Aggregate
		Outstanding			Remaining Contractual		Exercise Price		Intrinsic
					Life (Years)				Value
	$1.00 –   5.00		2,671,959			4.78	$	3.03
	$5.01 – 10.00		906,500			3.66	$	6.3
			3,578,459						$	7,759,365
Summary of Non-Vested Stock Options	'
	Nonvested stock options as of December 31, 2013, and changes during the year then ended, are as follows:
	Nonvested Shares	Shares			Weighted Average		Intrinsic
					Grant Date Fair		Value
					Value
	Nonvested at January 1, 2013		854,640
	Granted		278,794
	Vested		(342,538	)
	Forfeited		(176,428	)
	Nonvested at December 31, 2013		614,468		$	2.59	$	1,386,415
Summary of Warrants Outstanding to Purchase Common Stock	'
	Warrants outstanding and exercisable at December 31, 2013 are as follows:
	Range of Exercise Prices	Number			Weighted Average		Weighted Average		Aggregate
		Outstanding			Remaining Contractual		Exercise Price		Intrinsic
					Life (Years)				Value
	$0.00 – 5.00		2,356,792			1.44	$	3.92	$	4,640,492

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Commitment on the Remaining Operating Lease	'
	The future minimum commitment on the remaining operating lease at December 31, 2013 is as follows:
	Years ending December 31,
	2014	$	118,665
	2015		29,806
		$	148,471

Selected_Quarterly_Results_Una1

Selected Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Results	'
	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data):
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Revenue	$	1,622		$	2,764		$	2,997		$	3,973
	Gross profit		1,247			2,074			2,354			3,599
	Loss from operations		(13,712	)		(13,808	)		(17,083	)		(11,799	)
	Net loss		(12,723	)		(13,415	)		(18,486	)		(12,770	)
	Basic loss per share		(0.34	)		(0.35	)		(0.49	)		(0.33	)
	Diluted loss per share		(0.34	)		(0.35	)		(0.49	)		(0.33	)
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Revenue	$	16,518		$	16,298		$	1,875		$	19,851
	Gross profit		16,143			15,923			1,500			19,066
	Income (loss) from operations		8,565			7,148			(14,059	)		5,408
	Net income (loss)		6,751			3,783			(17,477	)		8,596
	Basic income (loss) per share		0.23			0.13			(0.58	)		0.26
	Diluted income (loss) per share		0.23			0.12			(0.58	)		0.19

Nature_of_Business_and_Summary3

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended			1 Months Ended	12 Months Ended
	31-May-12	Jan. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Agreement			Arcion License Agreement [Member]	Minimum [Member]	Maximum [Member]
Basis Of Presentation [Line Items]	'	'	'	'	'	'	'	'
Common Stock, par value	'	'	$0.00	$0.00	$2.91	'	'	'
FDIC insurance coverage amount	'	'	$250,000	'	'	'	'	'
Net deposit amount exceeds specified amount under FDIC	'	'	22,800,000	'	'	'	'	'
Non-refundable up-front license payment	15,000,000	30,000,000	'	'	'	'	'	'
Recognized Deferred revenue related to research and development services rendered	'	14,400,000	'	'	'	'	'	'
Deferred amount earned out of total deferred revenue	'	'	6,300,000	5,200,000	'	'	'	'
Revenue recognized from delivery of license rights to Endo	'	15,600,000	'	'	'	'	'	'
Payment to Arcion in unregistered Common Stock	'	'	'	'	'	2,100,000	'	'
License and Development agreements	'	'	2	'	'	'	'	'
Trade accounts receivable	'	'	99.60%	83.00%	'	'	'	'
Estimated useful lives of equipment	'	'	'	'	'	'	'3 years	'10 years
Idle equipment net	'	'	2,844,718	'	'	'	'	'
Impairment charges recognized on finite lived intangibles assets	'	'	0	0	0	'	'	'
Amortization expense on other intangible assets	'	'	1,000,000	1,000,000	900,000	'	'	'
Goodwill impairment charges	'	'	$0	$0	$0	'	'	'
Outstanding stock options and warrants	'	'	6,549,719	5,509,075	7,847,052	'	'	'

Nature_of_Business_and_Summary4

Nature of Business and Summary of Significant Accounting Policies - Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2013
Licenses [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated Useful Lives	'15 years
U.S. Product Rights [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated Useful Lives	'10 years
U.S. Product Rights [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated Useful Lives	'12 years
Eu Product Rights [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated Useful Lives	'11 years

Nature_of_Business_and_Summary5

Nature of Business and Summary of Significant Accounting Policies - Estimated Aggregate Future Amortization Expenses for Other Intangible Assets (Detail) (USD $)	Dec. 31, 2013
Accounting Policies [Abstract]	'
2014	$970,356
2015	970,356
2016	970,356
2017	970,356
2018	970,356
Thereafter	344,718
Total	$5,196,498

Nature_of_Business_and_Summary6

Nature of Business and Summary of Significant Accounting Policies - Reconciliation of the Numerators and Denominators of the Basic and Diluted (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basic:	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income attributable to common stockholders	'	'	'	'	'	'	'	'	($57,393,613)	$1,652,181	($23,325,116)
Weighted average common shares outstanding	'	'	'	'	'	'	'	'	37,941,044	30,546,581	28,322,477
Basic earnings per common share	($0.33)	($0.49)	($0.35)	($0.34)	$0.26	($0.58)	$0.13	$0.23	($1.51)	$0.05	($0.82)
Effect of dilutive securities:	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income attributable to common stockholders	'	'	'	'	'	'	'	'	-57,393,613	1,652,181	-23,325,116
Adjustments to income for dilutive options and warrants	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income attributable to common stockholders Diluted	'	'	'	'	'	'	'	'	($57,393,613)	$1,652,181	($23,325,116)
Weighted average common shares outstanding	'	'	'	'	'	'	'	'	37,941,044	30,546,581	28,322,477
Effect of dilutive options and warrants	'	'	'	'	'	'	'	'	'	142,654	'
Diluted weighted average common shares outstanding	'	'	'	'	'	'	'	'	37,941,044	30,689,235	28,322,477
Diluted earnings per common share	($0.33)	($0.49)	($0.35)	($0.34)	$0.19	($0.58)	$0.12	$0.23	($1.51)	$0.05	($0.82)

Nature_of_Business_and_Summary7

Nature of Business and Summary of Significant Accounting Policies - Black Scholes Options-Pricing Model, Assumptions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Dividend yield	'	'	'
Minimum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Expected price volatility	77.59%	81.96%	69.05%
Risk-free interest rate	0.70%	0.62%	0.90%
Weighted average expected life in years	'5 years	'5 years	'5 years
Maximum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Expected price volatility	81.65%	83.69%	77.75%
Risk-free interest rate	1.60%	1.02%	1.99%
Weighted average expected life in years	'6 years	'6 years	'6 years

Liquidity_and_Managements_Plan1

Liquidity and Management's Plans - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Nov. 30, 2013

Jul. 05, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Nov. 30, 2013

Feb. 07, 2014

Jan. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Dec. 31, 2013

Jan. 23, 2014

Feb. 28, 2014

Jan. 31, 2014

Nov. 30, 2012

Maximum [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Series A Non-Voting Convertible Preferred Stock [Member]

Equity Option [Member]

Equity Option [Member]

Liquidity and Management's Plans [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from secured loan facility from Midcap

'

'

$19,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development reimbursements under the Endo agreements

'

'

2,782,830

'

'

'

'

'

'

'

'

'

'

'

'

'

Net royalties under the Meda agreements

'

'

1,773,215

1,082,742

2,716,452

'

'

'

'

'

'

'

'

'

'

'

Contract revenue from licensing and supply agreement

'

'

300,000

'

300,000

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock options

'

'

357,281

2,054,100

349,676

'

'

'

'

'

'

'

'

2,200,000

2,200,000

'

Upfront and milestone payments from Endo license agreement

'

'

'

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, par value

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

$0.00

Net proceeds from registered direct offering of Common stock and newly designated series

'

'

'

38,400,000

'

'

'

'

4,000,000

'

'

'

'

'

'

'

Deferred contract revenue

'

'

'

17,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock warrants

'

'

50,000

921,019

1,749,259

'

'

'

'

2,600,000

2,600,000

50,000

'

'

'

'

Net proceeds from a private placement offering of Common Stock in March 2011

'

'

'

'

14,000,000

'

'

'

'

'

'

'

'

'

'

'

Research revenues from various contractor agreements

'

'

'

13,375

227,668

'

'

'

'

'

'

'

'

'

'

'

Secured loan facility

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds in the aggregate amount

'

19,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's securities for shelf registration

'

'

'

'

'

'

75,000,000

'

'

'

'

'

'

'

'

'

Common Stock, shares issued

'

'

38,204,384

37,497,703

'

'

'

7,500,000

658,489

'

658,489

'

'

'

'

'

Universal shelf registration common stock potential value for utilization at market offering programme

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payment from Endo

'

'

'

'

'

'

'

'

'

10,000,000

'

'

10,000,000

'

'

'

Common stock exercised

'

'

'

'

'

'

'

'

515,000

515,000

515,000

10,000

'

'

'

'

Stock options exercised

'

'

357,281

2,054,100

349,676

'

'

'

'

'

'

'

'

700,000

700,000

'

Common Stock, shares par value

'

'

$0.00

$0.00

$2.91

'

'

$0.00

'

'

'

'

'

'

'

'

Number of common stock shares sold

'

'

'

'

'

'

'

$8

'

'

'

'

'

'

'

'

Proceeds from sale of common stock

'

'

'

'

'

'

'

60,000,000

'

'

'

'

'

'

'

'

Closing price of the Common Stock, percentage

'

'

'

'

'

'

'

3.10%

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

23,175,809

63,189,307

10,750,205

18,208,659

'

'

'

'

'

'

'

'

'

'

Cash from operations

'

'

-60,102,816

12,187,324

-23,274,994

'

'

'

'

'

'

'

'

'

'

'

Stockholders' equity

'

'

($812,351)

$49,777,213

$4,120,393

$9,786,330

'

'

'

'

'

'

'

'

'

'

Research_and_Development_Arran1

Research and Development Arrangements and Related Party Transactions - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2012	Jun. 30, 2012	Dec. 31, 2009
In Millions, except Share data, unless otherwise specified				Accentia Biopharmaceuticals, Inc [Member]	Accentia Biopharmaceuticals, Inc [Member]	Accentia Biopharmaceuticals, Inc [Member]	Bioral [Member]	Non- Bioral [Member]	Emezine Settlement Agreement [Member]
				Employee
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'	'	'	'	'	'
Consideration percentage of future potential revenues from related party	'	'	'	'	'	'	10.00%	3.50%	'
Number of employee shared for accounting and administrative staff	'	'	'	1	'	'	'	'	'
Payments for rent	'	'	'	$0.03	$0.06	$0.06	'	'	'
Shares of common stock of Biovest International, Inc.	10,000	281,865	601,120	'	'	'	'	'	2,000,000

Equipment_Summary_of_Equipment

Equipment - Summary of Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Less accumulated depreciation	($1,738,532)	($1,531,090)
Equipment, gross other than idle equipment	3,022,886	2,835,707
Equipment, net	178,168	2,835,707
Office and Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment, gross	4,761,418	4,366,797
Idle Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment, gross	($2,844,718)	'

Equipment_Additional_Informati

Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'
Depreciation	$207,441	$465,929	$444,527

Meda_License_Development_and_S1

Meda License, Development and Supply Agreements - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

31-May-12

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2009

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2012

31-May-12

ONSOLIS [Member]

ONSOLIS [Member]

US [Member]

EU [Member]

EU [Member]

EU [Member]

U.S. [Member]

Milestones [Member]

Meda License Development and Supply Agreement [Member]

Meda License Development and Supply Agreement [Member]

EU [Member]

EU [Member]

EU [Member]

ONSOLIS [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent expiration year

'

'

'2020

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate milestones and services revenue recognized

'

'

$6,799,838

$53,446,309

$318,800

'

'

$59,700,000

$17,500,000

'

'

'

'

$2,500,000

$2,500,000

Remaining deferred revenue related to the EU Media arrangement milestones

'

14,400,000

'

'

'

'

'

'

'

'

'

'

1,300,000

'

'

Additional revenues in milestones

15,000,000

30,000,000

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

Product royalty revenues

'

'

1,773,215

1,082,742

2,716,452

1,800,000

1,100,000

'

'

'

'

'

'

'

'

Cost of product royalties

'

'

2,082,183

1,909,785

1,756,629

2,100,000

1,900,000

'

'

'

'

'

'

'

'

Estimated portion of upfront payments

'

'

'

'

'

'

'

'

'

$100,000

'

$1,200,000

'

'

'

Shelf life of the product

'

'

'24 months

'

'

'

'

'

'

'

'

'

'

'

'

Period for application review

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

Endo_License_and_Development_A1

Endo License and Development Agreement - Additional Information (Detail) (USD $)	12 Months Ended							1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	31-May-12	Jan. 17, 2012	Feb. 28, 2014	Jan. 23, 2014	31-May-12
	Milestone					Subsequent Event [Member]	Subsequent Event [Member]	Endo License and Development Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]	'	'	'	'	'	'	'	'
Non-refundable payment received	'	'	'	'	$30,000,000	'	'	'
Potential milestone payments	95,000,000	'	'	'	'	'	'	'
Number of potential milestone payments	6	'	'	'	'	'	'	'
Potential milestone payments on intellectual property rights	35,000,000	'	'	'	'	'	'	'
Potential milestone payments on issuance of patent	15,000,000	'	'	15,000,000	'	'	'	'
Potential milestone payment receivable clinical development	20,000,000	'	'	'	'	'	'	'
Potential milestone payment receivable regulatory events	40,000,000	'	'	'	'	'	'	'
Payment receivable on achievement of potential sales milestones	55,000,000	'	'	'	'	'	'	'
Number of potential sales milestones	4	'	'	'	'	'	'	'
Recognized up-front payment allocated to the license	15,600,000	'	'	'	'	'	'	'
Recognized up-front payment to clinical trial material and development services	14,400,000	'	'	'	'	'	'	'
Upfront payment	0	'	'	'	'	'	'	'
Aggregate milestones and services revenue recognized	6,799,838	53,446,309	318,800	'	'	'	'	15,000,000
Estimated amount recognized against clinical services deliverable	6,300,000	5,200,000	'	'	'	'	'	'
Deferred revenue income of the research and development activities	2,900,000	'	'	'	'	'	'	'
Term of Endo Agreement	'10 years	'	'	'	'	'	'	'
Extended patent on drug delivery technology	'2020 to 2027	'	'	'	'	'	'	'
Milestone payment regarding licensing agreement	'	'	'	'	'	$10,000,000	$10,000,000	'

Arcion_License_Agreement_Addit

Arcion License Agreement - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Common stock locking period	'9 months	'	'
Milestone payments increased	$8,000,000	'	'
Research and development expense	53,326,777	35,365,662	20,805,177
US [Member]	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Potential Payments upon achieving certain pre-determined sales thresholds in the U.S	60,000,000	'	'
US [Member] | Minimum [Member]	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Milestone Sales	200,000,000	'	'
Milestone payment receivable from sublicenses	70,000,000	'	'
Arcion License Agreement [Member]	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Share issued to Arcion	500,516	'	'
Fair market value of unregistered shares issued	2,100,000	'	'
Potential payments upon filing and acceptance	2,500,000	'	'
Royalty term description	'The royalty term for any given country is the later of (i) the first date there are no valid claims against any Arcion patent, (ii) expiration of patent exclusivity or (iii) tenth anniversary of the first commercial sale.	'	'
Research and development expense	2,100,000	'	'
Arcion License Agreement [Member] | Minimum [Member]	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Potential milestone payment upon FDA approval	17,500,000	'	'
Arcion License Agreement [Member] | Maximum [Member]	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Potential milestone payment upon FDA approval	$35,000,000	'	'

Other_License_Agreements_and_A1

Other License Agreements and Acquired Product Rights - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Feb. 28, 2012

Sep. 30, 2007

Jul. 31, 2009

Dec. 31, 2013

Sep. 30, 2007

Oct. 07, 2010

Nov. 30, 2011

Sep. 30, 2013

Dec. 31, 2013

31-May-10

Dec. 31, 2013

Dec. 31, 2013

North American [Member]

North America [Member]

North America [Member]

North America [Member]

TTY License and Supply Agreement [Member]

TTY License and Supply Agreement [Member]

TTY License and Supply Agreement [Member]

TTY License and Supply Agreement [Member]

Kunwha License Agreement [Member]

Kunwha License Agreement [Member]

Tolmar Notes [Member]

To be Paid Within 30 Days of Regulatory Approval of the First Product [Member]

Other License Agreements And Acquired Product Rights [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date of the agreement

'

'

'

'

'

'

'

'

'

23-Jul-27

'

'

Upfront payment

'

'

'

'

'

$0.30

'

'

'

'

$0.30

'

Up-front payment net of tax

'

'

'

'

'

'

'

'

'

'

0.25

'

Milestone payments

'

'

'

'

'

1.3

'

'

'

'

1.3

'

Milestone payments net of tax

'

'

'

'

'

'

'

'

'

'

1.1

'

Term of the agreement

'

'

'

'

'

'

'

'

'15 years

'

'

'

Milestone payment received

'

'

'

'

'

'

0.3

0.3

'

'

'

'

Purchase price of rights and assets

'

7

'

'

'

'

'

'

'

'

'

'

Cash paid as consideration

'

3

'

'

'

'

'

'

'

'

'

'

Promissory note to be paid

'

4

'

'

2

'

'

'

'

'

'

'

Promissory note paid

'

'

2

'

'

'

'

'

'

'

'

'

Promissory Note Due Period

'

'

'

'30 days

'

'

'

'

'

'

'

'

Cumulative net sales for determining payment of promissory note

'

30

'

'

'

'

'

'

'

'

'

'

Amount outstanding under the Tolmar note

'

'

'

2

'

'

'

'

'

'

'

'

Notes settlement amount

1.05

'

'

'

'

'

'

'

'

'

'

'

Notes Issued Outstanding Amount

'

'

'

'

'

'

'

'

'

'

'

$2

MidCap_Secured_Loan_Facility_A

MidCap Secured Loan Facility - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 05, 2013	Dec. 31, 2013
Debt [Line Items]	'	'
Secured loan facility	$20,000,000	'
Net proceeds in aggregate amount	19,800,000	'
Unregistered shares of common stock	'	357,356
Warrant exercise price	'	4.2
Days of volume-weighted average share price	'	'20-day volume-weighted average share price of the Common Stock prior to the closing of the Loan
Warrant exercisable term	'	'5 years
Amortization Period of Discount	'	'3 years
Term of loan	'	'36 months
Interest rate	'	8.45%
LIBOR floor Rate	'	0.50%
Interest rate at period end	'	8.95%
Final payment fee Rate	'	3.50%
Closing fee	'	0.50%
Exit fee percentage recorded as deferred loan costs	'	3.50%
Loan amount prepaid in the first year of the Loan	'	5.00%
Loan amount prepaid in each year thereafter	'	3.00%
Prepayment of principal amount of the Loan rate	'	50.00%
Cash prepayment fee of principal amount of Loan	'	2.00%
Percentage of prepayment amount to purchase shares of Common Stock	'	2.00%
Mid Cap [Member]	'	'
Debt [Line Items]	'	'
Secured loan facility	20,000,000	'
Net proceeds in aggregate amount	19,800,000	'
Unregistered shares of common stock	'	357,356
Warrant exercise price	'	4.2
Notice Period	'	'10 days
Rate of interest Applicable to obligations	'	4.00%
Secured loan facility due to Midcap	'	20,000,000
Unamortized discount net	'	$821,961

MidCap_Secured_Loan_Facility_S

MidCap Secured Loan Facility - Schedule Showing Allocation of Secured Loan Facility to Notes Payable and Midcap Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Debt [Line Items]	'
Total proceeds	$20,000,000
Note Payable [Member]	'
Debt [Line Items]	'
Total proceeds	19,013,648
Midcap Warrant [Member]	'
Debt [Line Items]	'
Total proceeds	$986,352

MidCap_Secured_Loan_Facility_S1

MidCap Secured Loan Facility - Schedule of Fair Value of Warrants Based Upon the Black Scholes Valuation Model Assumptions (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Market price of stock	$4.41
Term of warrant	'5 years
Volatility	81.05%
Risk free interest rate	2.90%

MidCap_Secured_Loan_Facility_F

MidCap Secured Loan Facility - Future Maturities Of MidCap Obligation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Debt [Line Items]	'
Total Midcap obligation	$7,333,333
Mid Cap [Member]	'
Debt [Line Items]	'
2014	7,333,333
2015	8,000,000
2016	4,666,667
Total maturities	20,000,000
Unamortized discount	-821,961
Total Midcap obligation	$19,178,039

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Components of (Expense) Income of Derivative Financial Instruments (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Loans And Allowance For Loan By Class Individually And Collectively Evaluated For Impairment [Line Items]	'	'	'
Derivative Gain	$121,228	($5,594,152)	$3,463,453
Free Sanding Derivatives (warrants) [Member]	'	'	'
Schedule Of Loans And Allowance For Loan By Class Individually And Collectively Evaluated For Impairment [Line Items]	'	'	'
Derivative Gain	-50,300	-338,500	-910,231
Free Standing Derivatives Warrants Liabilities [Member]	'	'	'
Schedule Of Loans And Allowance For Loan By Class Individually And Collectively Evaluated For Impairment [Line Items]	'	'	'
Derivative Gain	$171,528	($5,255,652)	$4,373,684

Derivative_Financial_Instrumen3

Derivative Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
Assets	'	'
Derivative asset (warrant)	'	$50,300
Liabilities	'	'
Derivative liabilities	4,315,183	4,497,977
Level 1 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	'
Liabilities	'	'
Derivative liabilities	'	'
Level 2 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	50,300
Liabilities	'	'
Derivative liabilities	4,315,183	4,497,977
Level 3 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	'
Liabilities	'	'
Derivative liabilities	'	'

Derivative_Financial_Instrumen4

Derivative Financial Instruments - Reconciliation of Beginning and Ending Balances of Assets and Liabilities Measured at Fair Value Using Significant Observable Inputs (Detail) (Midcap Warrant [Member], Level 2 [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Midcap Warrant [Member] | Level 2 [Member]	'	'
Fair Value Measurement Inputs Disclosure [Line Items]	'	'
Warrant asset, Beginning balance	$50,300	$388,540
Decrease in fair value of warrants	-50,300	-338,240
Warrant asset, Ending balance	'	50,300
Warrant liability, Beginning balance	4,497,977	279,302
Decrease due to exercise of warrants	-11,266	-1,037,237
Expiration of warrants	'	'
Increase (Decrease) in fair value of warrants	-171,528	5,255,912
Warrant liability, Ending balance	$4,315,183	$4,497,977
Warrant asset, Beginning balance, Number of warrants	'	2,000,000
Decrease in fair value of warrants, Number of warrants	-2,000,000	'
Warrant asset, Ending balance, Number of warrants	'	2,000,000
Warrant liability, Beginning balance, Number of warrants	'	3,246,301
Decrease due to exercise of warrants, Number of warrants	-10,000	-236,865
Expiration of warrants, Number of warrants	'	-1,000,000
Increase (Decrease) in fair value of warrants, Number of warrants	'	'
Warrant liability, Ending balance, Number of warrants	1,999,436	2,009,436

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax [Line Items]	'	'	'
Federal statutory income tax rate	34.00%	34.00%	34.00%
Income tax expense	'	($129,120)	'
Deferred tax asset reduced by valuation allowance	50.00%	'	'
Domestic Country [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Operating Loss	109,000,000	'	'
Net operating loss used to offset taxable income	1,500,000	'	'
State and Local Jurisdiction [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Operating Loss	100,000,000	'	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory income tax rate	34.00%	34.00%	34.00%
State taxes, net of federal benefit	3.45%	3.45%	3.45%
Permanent differences-derivative loss (gain)	0.11%	110.51%	7.02%
Permanent differences-other	-1.07%	44.12%	-2.76%
Research and development ("R&D") credit	4.91%	-129.12%	2.92%
Other	0.64%	-30.89%	-6.63%
Valuation allowance	-42.04%	-24.82%	-38.00%
Federal statutory income tax rate, Total	0.00%	7.25%	0.00%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Deferred revenue	$1,576,186	$4,010,493
Basis difference in equipment	-890,387	-926,735
Basis difference in intangibles	-501,709	-618,403
Accrued liabilities and other	418,300	263,364
R&D credit	10,366,432	8,720,314
Stock options	2,199,794	1,557,756
Net operating loss carry-forward (NOL)	40,494,523	16,575,544
Gross, Deferred Tax Assets	53,663,139	29,582,333
Less: valuation allowance	-53,663,139	-29,582,333
Net of Valuation Allowance	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional information (Detail) (USD $)

12 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Nov. 30, 2013

Dec. 31, 2012

Jan. 31, 2014

Feb. 07, 2014

Dec. 31, 2013

Jul. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 11, 2011

Nov. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 03, 2012

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Mid Cap [Member]

Equity Incentive Plan [Member]

Equity Incentive Plan [Member]

LTIP [Member]

LTIP [Member]

LTIP [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued in the offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,807,693

'

6,791,887

'

'

Company's securities for shelf registration

'

'

'

'

'

'

'

'

$75,000,000

'

'

'

'

'

'

'

'

'

'

$75,000,000

'

'

'

Common Stock, shares issued

38,204,384

37,497,703

'

'

'

'

'

'

'

'

658,489

7,500,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

'

38,373,014

13,996,773

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Series A Preferred shares

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized shares of Preferred stock

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,290,700

'

Series A Preferred shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,709,300

2,709,300

Liquidation, dissolution or winding up, holders of the Series A Preferred per share payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

Restricted stock units ("RSUs") issued to directors and key employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57,500

'

1,078,000

978,000

'

'

'

'

'

Restricted Stock Unit issuance cost

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

900,000

30,000

'

'

'

'

'

Company Issued, RSUs

'

'

'

118,853

'

1,078,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair market value of shares granted

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options vesting Remaining period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued, RSUs

'

'

'

'

3,125

63,853

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of RSU

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of RSU

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company Issued

'

'

'

'

'

55,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock units reserve for future Officers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

RSU's Vested as per Performance criteria during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years

'

'

'

'

'

'

Number of RSUs Vested

342,538

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,968

'

'

'

'

'

'

Covers a shares of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

4,200,000

'

'

'

'

'

'

'

'

'

Common Stock option outstanding and exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

3,192,596

'

'

'

'

'

'

'

'

'

Option awarded term

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value of options granted

$3.28

$1.97

$3.43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options granted in period with exercise price below market price

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested share-based compensation awards granted

4,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested share-based compensation awards granted year

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of shares

357,356

'

'

'

'

'

'

'

'

'

'

'

357,356

'

'

'

'

'

'

'

'

'

'

Common Stock at a price

4.2

'

'

'

'

'

'

'

'

'

'

'

4.2

'

'

'

'

'

'

'

'

'

'

Warrants fair value

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Warrants exercised to purchase shares of common stock

10,000

281,865

601,120

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price per shares of common stock

$5

'

'

'

'

'

'

$3

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants classified as derivative liability

'

$236,865

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price per shares of common stock

$0.00

$0.00

$2.91

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Outstanding at beginning of period	4,279,919	4,553,251	4,311,539
Number of Shares, Granted	278,794	'	'
Number of Shares, Exercised	-115,667	-789,305	-129,888
Number of Shares, Forfeitures	-250,119	-250,741	-76,937
Number of Shares, Outstanding at end of period	4,192,927	4,279,919	4,553,251
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$3.70	$3.66	$3.65
Weighted average Exercise Price Per Share, Exercised	$3.25	$2.60	$2.69
Weighted Average Exercise Price Per Share, Forfeitures	$2.89	$3.26	$3.09
Weighted Average Exercise Price Per Share, Outstanding at end of period	$3.82	$3.70	$3.66
Aggregate Intrinsic Value, Outstanding at end of period	$9,145,780	$4,572,205	'
Officers and Directors [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Granted	55,659	281,174	209,619
Weighted Average Exercise Price Per Share, Granted	$5.39	$2.36	$3.44
Others [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Granted	223,135	485,540	238,918
Weighted Average Exercise Price Per Share, Granted	$4.47	$2.80	$3.41

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Stock Options Outstanding (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013
				$ 1.00 - 5.00 [Member]	$ 5.01 - 10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'
Range of Exercise Prices, minimum	'	'	'	$1	$5.01
Range of Exercise Prices, maximum	'	'	'	$5	$10
Number Outstanding	4,192,927	'	'	3,230,768	962,159
Weighted Average Remaining Contractual Life (Years)	'	'	'	'5 years 5 months 23 days	'4 years 7 days
Weighted Average Exercise Price	'	'	'	$3.10	$6.25
Aggregate Intrinsic Value	$9,145,780	$4,572,205	'	'	'

Stockholders_Equity_Summary_of2

Stockholders' Equity - Summary of Stock Options Exercisable (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Exercisable	3,578,459
Aggregate Intrinsic Value	$7,759,365
$ 1.00 - 5.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$1
Range of Exercise Prices, maximum	$5
Number Exercisable	2,671,959
Weighted Average Remaining Contractual Life (Years)	'4 years 9 months 11 days
Weighted Average Exercise Price	$3.03
$ 5.01 - 10.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$5.01
Range of Exercise Prices, maximum	$10
Number Exercisable	906,500
Weighted Average Remaining Contractual Life (Years)	'3 years 7 months 28 days
Weighted Average Exercise Price	$6.30

Stockholders_Equity_Summary_of3

Stockholders' Equity - Summary of Non-Vested Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares [Roll Forward]	'
Nonvested at Beginning of period	854,640
Granted	278,794
Vested	-342,538
Forfeited	-176,428
Nonvested at End of period	614,468
Weighted Average Grant Date Fair Value, Nonvested at December 31, 2013	$2.59
Nonvested at December 31, 2013, Aggregate Intrinsic Value	$1,386,415

Stockholders_Equity_Summary_of4

Stockholders' Equity - Summary of Warrants Outstanding to Purchase Common Stock (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2013
					$ 0.01 - 5.00 [Member]	Midcap Warrant [Member]
						$ 0.01 - 5.00 [Member]
Warrants, by Exercise Price Range [Line Items]	'	'	'	'	'	'
Range of Exercise Prices, minimum	'	'	'	'	$0	'
Range of Exercise Prices, maximum	'	'	'	'	$5	'
Number Outstanding	4,192,927	4,279,919	4,553,251	4,311,539	'	2,356,792
Weighted Average Remaining Contractual Life (Years)	'	'	'	'	'	'1 year 5 months 9 days
Weighted Average Exercise Price	$3.82	$3.70	$3.66	$3.65	'	$3.92
Aggregate Intrinsic Value	$9,145,780	$4,572,205	'	'	'	$4,640,492

Retirement_Plan_Additional_Inf

Retirement Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Sale Of Subsidiary [Abstract]	'	'	'
Employers' sponsors contribution retirement plan	90.00%	'	'
Contribution to retirement plan percentage of employee contribution	100.00%	'	'
Percentage of employee contribution to retirement plan	5.00%	'	'
Employers' sponsors contribution retirement plan amount	$0.20	$0.10	$0.10

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			CDC [Member]	Minimum [Member]	Corporate Segment [Member]	Corporate Segment [Member]
				CDC [Member]
Contingencies And Commitments [Line Items]	'	'	'	'	'	'
Lease expiration amendment period	'24 months	'	'	'	'	'
Lease, expiration date	'	'	'	'	1-Jan-13	'
Lease expense	'	'	'	'	$100,000	$100,000
Royalties received	'	300,000	18,750	375,000	'	'
Granted royalty on sales of the next BEMA product	'	'	1.00%	'	'	'
Royalty repurchase minimum period	'	'	'6 months	'	'	'
Net sales of Next BEMA Product	'	'	7,500,000	'	'	'
Over Payment of Royalty Costs	'	$1,100,000	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Commitment on the Remaining Operating Lease (Detail) (USD $)	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
2014	$118,665
2015	29,806
Total operating lease	$148,471

Selected_Quarterly_Results_Una2

Selected Quarterly Results (Unaudited) - Selected Quarterly Results (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selected Quarterly Financial Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$3,973,000	$2,997,000	$2,764,000	$1,622,000	$19,851,000	$1,875,000	$16,298,000	$16,518,000	$11,355,883	$54,542,426	$3,262,920
Gross profit	3,599,000	2,354,000	2,074,000	1,247,000	19,066,000	1,500,000	15,923,000	16,143,000	'	'	'
Income (loss) from operations	-11,799,000	-17,083,000	-13,808,000	-13,712,000	5,408,000	-14,059,000	7,148,000	8,565,000	-56,401,941	7,061,790	-26,987,976
Net income (loss)	($12,770,000)	($18,486,000)	($13,415,000)	($12,723,000)	$8,596,000	($17,477,000)	$3,783,000	$6,751,000	($57,393,613)	$1,652,181	($23,325,116)
Basic income (loss) per share	($0.33)	($0.49)	($0.35)	($0.34)	$0.26	($0.58)	$0.13	$0.23	($1.51)	$0.05	($0.82)
Diluted income (loss) per share	($0.33)	($0.49)	($0.35)	($0.34)	$0.19	($0.58)	$0.12	$0.23	($1.51)	$0.05	($0.82)

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation And Qualifying Accounts [Abstract]	'	'	'
Balance at beginning of the period	$29.58	$30.13	$21.27
Charged to income	'	'	'
Charged to other accounts	24.08	-0.55	8.86
Balance at end of the period	$53.66	$29.58	$30.13